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When dietary fatty acids are absorbed by intestinal enterocytes, they are re-assembled 
into complex lipids such as phospholipids, cholesterol esters, and triglycerides. Although the 
cellular machinery required for these processes is well known, the mechanisms regulating the 
partitioning of individual fatty acids among the thousands of possible complex lipid products are 
not as well understood. Metabolic labeling of dietary lipids, historically performed using 
radioactive reagents or expensive stable isotopes, is a key technique for examining the 
biochemical behavior of individual fatty acids in the context of a physiologically relevant mixed-
lipid diet. Likewise, fluorescent lipids have been established as important tools for live imaging 
of the trafficking and spatial deposition of dietary lipids, yet their metabolism has not been fully 
characterized. I have developed a novel HPLC-based quantitative metabolic labeling method in a 
larval zebrafish model, wherein the same fluorescent lipid reagents and delivery methods may be 
used for biochemical and live imaging experiments. The characterization of fluorescent fatty acid 
metabolism described here opens the way for more widespread use of fluorescent lipids in 
metabolic studies. In this thesis I review the current literature on the zebrafish as a model for lipid 
uptake and metabolism. This review includes my own analysis and interpretation of a recently 
published developmental lipidomics data set.  I then describe the application of metabolic 
labeling with fluorescent lipids toward a greater understanding of dietary lipid partitioning in the 
intestinal enterocytes, specifically addressing the interactions among dietary fatty acids, 
cholesterol, and ethanol. Preliminary results suggest that phospholipid synthesis from dietary 
fatty acids is increased in larval zebrafish exposed to ethanol before feeding. Future work will 
address potential physiological effects of this interaction between ethanol and dietary fatty acid 
partitioning. Additionally, I report results of a collaborative study in which HPLC lipid profiling 
methods initially developed in zebrafish were expanded into a mouse model. This enabled 
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measurement of changes in individual plasma lipid species resulting from perturbation of a 
putative lipid transport mechanism in the intestinal enterocytes. These diverse applications of the 
metabolic labeling methods I have developed demonstrate significant contributions to the lipid 
biology field: I have expanded both the amount and type of data that can be obtained using HPLC 
lipidomics, creating a relatively low-cost and high-throughput alternative to metabolic labeling 
with mass spectrometry analysis. Furthermore, ongoing work may contribute to greater 
understanding of both potentially beneficial interactions between ethanol and dietary lipids (e.g. 
the Mediterannean diet hypothesis) and possible diet-driven variability in the progression of 
alcoholic liver disease. 
 
Readers: Steven Farber, G. William Wong, Marnie Halpern, David Cohen 
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	 In this thesis I describe novel lipidomics and metabolic labeling techniques that I 
developed in the larval zebrafish model. This work has addressed a need in the lipidomics field 
for a midpoint between expensive and resource-intensive liquid chromatography-mass 
spectrometry (LC-MS) lipidomics (which may yield so much information as to make 
interpretation unnecessarily difficult due to signal to noise issues) and thin-layer chromatography 
or less precise mass spectrometry techniques that either only give information on lipid classes 
and/or fatty acids.  
In Chapter 1 I have reviewed the current literature on the embryonic and larval zebrafish 
as models for lipid absorption, metabolism, and transport. Additionally, drawing on a published 
LC-MS lipidomic data set, I have analyzed and interpreted trends in individual phospholipids 
over the course of yolk absorption by the developing zebrafish.  
Chapter 2 was originally published as a methods article in the Journal of Lipid Research, 
and presents a novel combined biochemical and live imaging method for the study of dietary lipid 
metabolism. Metabolic labeling, which is the delivery of tagged analogs of nutrients to an animal 
or cell culture model so that the labeled molecules and their products can be assayed in context, is 
especially important for the study of lipid metabolism. All naturally-occuring foods and internal 
sources of lipid (e.g., the embryonic zebrafish yolk) are mixtures of various types of complex 
lipids carrying a wide variety of different fatty acids. Historically, isotopically labeled fatty acids 
have been used as metabolic labels to study the biochemical processing of individual fatty acids 
in the context of a mixed-nutrient diet, and the predominant application of fluorescently labeled 
lipids has been live imaging to study the spatial distribution of the products of dietary lipids. 
Expanding upon existing techniques, I have developed novel methods for metabolic labeling with 
fluorescent lipids: This is the first published application of these reagents capable of yielding both 
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a detailed biochemical profile of the products of  individual dietary fluorescent fatty acids and 
live imaging data showing the spatial deposition of fluorescent lipids from the same experiment. I 
then used these methods to investigate the influence of nutritional context and the type of 
fluorescent tag on the partitioning of dietary fluorescent fatty acids into complex lipids.  
Additionally, I describe a novel approach to studying cholesterol metabolism by measuring 
cholesterol esterification with fluorescent fatty acids.  
Chapter 3, reprinted from a research article in Disease Models and Mechanisms, includes 
description of a high-throughput method I developed for quantitating individual free fatty acids 
and cholesterol esters in mouse plasma and tissue lipid extracts. We used this method to 
investigate effects of diet and disrupted putative lipid transport systems on plasma, liver, and 
adipose tissue lipid composition in mice.  
Chapter 4 describes ongoing work, which is the first investigation of how ethanol may 
alter metabolic channeling of individual dietary fatty acids that occurs as they are taken up by 
intestinal enterocytes. Ethanol is known to interfere with lipid metabolism by causing hepatic 
steatosis, but how lipid metabolism may be affected in other tissues is less clear.  Preliminary 
results show a shift toward phospholipid synthesis from dietary fluorescent fatty acids in larval 
zebrafish exposed to ethanol. To close, I discuss experimental plans to investigate both the 
physiological implications and potential mechanisms for this interaction between ethanol and 
fatty acid metabolism.  
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CHAPTER 1 – LIPID UPTAKE, METABOLISM, AND 
TRANSPORT IN THE LARVAL ZEBRAFISH 
 
This chapter was submitted to the Journal of Endocrinology for publication as a review under the 
topic “Energy Homeostasis in Lower Vertebrates,” and is currently in review. 
Abstract 
 
The developing zebrafish is a well-established model system for studies of energy 
metabolism, and is amenable to genetic, physiological, and biochemical approaches.  For the first 
five days of life, nutrients are absorbed from its endogenous maternally deposited yolk. At five 
days post-fertilization, the yolk is exhausted and the larva has a functional digestive system 
including intestine, liver, gallbladder, pancreas, and intestinal microbiota. The transparency of the 
larval zebrafish, and the genetic and physiological similarity of its digestive system to that of 
mammals make it a promising system in which to address questions of energy homeostasis 
relevant to human health. For example, apolipoprotein expression and function is similar in 
zebrafish and mammals, and transgenic animals may be used to examine both the transport of 
lipid from yolk to body in the embryo, and the trafficking of dietary lipids in the larva. 
Additionally, despite the identification of many fatty acid and lipid transport proteins expressed 
by vertebrates, the cell biological processes that mediate the transport of dietary lipids from the 
intestinal lumen to the interior of enterocytes remain to be elucidated. Genetic tractability and 
amenability to live imaging and a range of biochemical methods make the larval zebrafish an 
ideal model in which to address open questions in the field of lipid transport, energy homeostasis 




 The developing digestive system of the embryonic and larval zebrafish is a well-
established model system for the study of vertebrate gastrointestinal physiology and metabolism.  
Metabolic and regulatory pathways for gastrointestinal system development, intestinal and liver 
cell differentiation, digestion, and nutrient uptake and transport are highly conserved between 
zebrafish and humans (1-7). Additionally, the transparency of the developing larva makes it ideal 
for live imaging experiments: The larval zebrafish has a functional and visible liver, pancreas, 
gallbladder, intestine, and intestinal microbiota by 5 days post-fertilization (dpf) when it begins to 
feed. The zebrafish is also amenable to the generation of transgenic and mutant lines through a 
variety of techniques including CRISPR and TALENs (8-10), and is suitable for large scale 
forward genetic screens due to its small size and high fertility (11). Finally, as the importance of 
the gut microbiome to studies of nutritional physiology is becoming increasingly clear; the larval 
zebrafish microbiota are well-characterized, and germ-free and gnotobiotic models are available 
(12). 
 The zebrafish zygote contains a large yolk cell which is absorbed over the first five days 
of life and supplies the developing embryo with nutrients. The yolk consists of a lipid and protein 
rich core with a cellular syncytium at its periphery, called the yolk syncytial layer (YSL). The 
YSL exports amino acids, hydrolyzes complex lipids to release fatty acids, and synthesizes 
lipoproteins, which export lipid to the developing embryo until it is able to feed independently 
(13). The intestine of the larval zebrafish is open at both ends and ready to absorb exogenous food 
at 5 dpf, though the non-enterocyte secretory cell populations do not differentiate until later larval 
stages (14). Once the intestinal tract is open, the gut microbiota are acquired from the media. At 
this time colonization occurs essentially immediately and is maintained throughout life with the 
main source of variation in bacterial community composition being changes in diet(15). 
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Both the embryonic and larval zebrafish are valuable models of lipid uptake and trafficking, 
respectively from the yolk cell and the diet. This review encompasses the roles of lipid 
remodeling, lipoproteins, intestinal lipid transport proteins, and the gut microbiota in lipid 
processing during zebrafish development. 
 
Yolk Lipid Uptake in the Embyronic and Larval Zebrafish 
	
	
Lipoproteins transport yolk lipids to the body in the developing zebrafish embryo	
	
The majority of the mass of a zebrafish zygote consists of the yolk, a lipid-rich structure 
that is gradually depleted by transport of its contents to the embryo as it develops into a free-
feeding larva. Yolk lipids are packaged into lipoproteins in the YSL before being exported to the 
body of the developing zebrafish. Lipoproteins are lipid-transporting structures consisting of a 
neutral lipid interior bounded by a phospholipid and cholesterol monolayer, carrying one or more 
apolipoproteins. Apolipoproteins mediate interactions among lipoproteins, cellular receptors, and 
lipid-processing enzymes. The zebrafish genome contains analogs of every major human 
apolipoprotein, but there are some differences in patterns of expression and function. Due to the 
teleost genome duplication, zebrafish have multiple paralogs of each apolipoprotein gene. There 
are 11 apolipoprotein genes in the apoB, apoA-IV, apoE, and apoA-I families, and all are 
expressed in the YSL (16)(Figure 1). Whole-mount in-situ hybridization reveals that expression 
of some apolipoprotein genes is localized to subregions of the YSL, suggesting a previously 
uncharacterized compartmentalization of this structure. For example, mRNA encoding apoA-IV 
appears to be specific to the yolk extension at earlier stages (though different paralogs in this 
family are concentrated here at different points in development) while members of the other 
apolipoprotein families are expressed more evenly throughout the YSL (16). The significance of 
these potential YSL subdomains has yet to be described, but it is possible that there is a  
)!
Figure 1. Zebrafish apolipoprotein genes are expressed in the yolk syncytial layer.  The 
developing zebrafish embryo gradually absorbs lipids from its yolk (a), which is surrounded 
by the YSL. At 1-5 dpf, the yolk ball is lengthened along the tail of the embryo forming the 
yolk extension (b). In situ hybridization reveals expression of all 11 zebrafish apolipoprotein 
genes in the apoB, apoA-IV, apoE, and apoA-I families in the YSL at 1 day post-fertilization. 
Line drawing reprinted from Miyares et al, 2014. In situ hybridization images adapted and 
reprinted from Otis et al, 2015, Figures 2-5. 
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relationship to the regionalization of the developing intestine.	 
 Although the expression of apolipoprotein genes in the developing embryo and larva has 
been thoroughly characterized, the lipoprotein profile at these stages is less well defined.  Most 
work on fish lipoproteins has focused on adults, likely due to the difficulty of obtaining adequate 
blood samples from larvae(17). Secretion of VLDL (very low-density lipoprotein) particles from 
the yolk has been demonstrated by electron microscopy (18, 19). The YSL also expresses apoA-I 
and apoA-II, which are found in HDL (high-density lipoprotein) particles and chylomicrons but 
not LDL (low-density lipoprotein) or VLDL (16, 20). ApoB, which is a component of 
chylomicrons, LDL, and VLDL, has a vital role in the export of yolk lipids. Microsomal 
triglyceride transfer protein (MTP) packages triglycerides into ApoB-containing lipoproteins. 
ApoB is degraded if it is not associated with lipid so, in the absence of MTP function, ApoB is 
not functional (21). In mtp-/- mutant zebrafish larvae, lipids are trapped in the yolk (characterized 
by retention of yolk volume, an increase in yolk opacity, and a reduction in neutral lipid in the 
body) and larvae do not survive beyond 5 days (22). (Additionally, unlike their wild-type 
siblings, mtp-/- embryos retain fluorescent fatty acid injected into the yolk and do not export it or 
its fluorescent products to the circulation (23).) The ability of mtp-/- larvae to grow and survive to 
5 dpf suggests that some lipid must be transported out of the yolk in order for membranes to be 
synthesized, possibly through the synthesis of HDL-like particles that contain ApoA-I and do not 
require MTP for their assembly. 
 
Lipid composition of the embryo changes over the course of yolk absorption 
According to a recently published developmental study of lipid composition performed 
by liquid chromatography-mass spectrometry (LC-MS), at the time of fertilization, embryo lipids 
are approximately 40% cholesterol, 35% phospholipid (PL), and 9% triglyceride (TG), with less 
abundant species including mono- and di-glycerides, cholesterol esters (CE), ceramides and 
lysophospholipids making up the remainder (24). Over the first five days of life, a linear decrease 
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in the molar amount of most lipid species is observed in the yolk with a corresponding increase in 
the embryonic/larval body. Some exceptions have been observed: TG in the body remains 
consistently low as it is depleted from the yolk, suggesting that yolk TGs are primarily broken 
down and either oxidized for energy or resynthesized into other lipid products. Interestingly, CE, 
the other “energy storage” lipid class, is exchanged evenly from the yolk to the body during this 
period of development (24). Cholesterol synthesis in animal cells is tightly controlled in response 
to the cholesterol content of membranes via regulation of HMG-CoA Reductase expression, and 
esterification is a major mechanism by which excess cholesterol is neutralized (25). One possible 
reason that CE is not depleted during the lecithotrophic (yolk-feeding) period of development is 
that breaking down CE for fatty acid oxidation would result in an overabundance of cholesterol. 
Favoring glycerolipids as an early energy source therefore would be important for cholesterol 
homeostasis, while CE from the yolk could be repackaged into intracellular lipid droplets for later 
oxidation, or storage in adipocytes. Free cholesterol in the yolk and the body decrease and 
increase respectively at the same apparent rate between 24 hours and 5 days of development, but 
the cholesterol content of the body at 5 dpf is less than the initial amount in the yolk (24). It is 
likely that this portion of the cholesterol is directed to synthesis of steroid hormones and bile, 
though these compounds were not measured in this study. 
Phospholipid dynamics in the developing embryo also appear to be more complex than 
simple yolk to body trafficking: while other phospholipid classes seem to move gradually from 
the yolk to the body, phosphatidylcholine (PC) levels in the yolk increase over the first 24 hours, 
then decrease over the next four days while remaining relatively constant in the body (24). 
Though the specific lipid composition of zebrafish embryonic lipoproteins has not been 
investigated, one possible explanation is that the initial increase in PC goes to building the outer 
monolayer on lipoproteins exported from the yolk. It is possible that when this lipoprotein-
associated PC reaches the body, it is in excess and is either oxidized or remodeled.  
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Although Fraher and colleagues’ published analysis of their LC-MS data set was limited 
to discussion of developmental changes in lipid classes, quantitation of all individual lipid species 
was published as a supplement to the manuscript. These data provide an opportunity to examine 
the changes in individual lipid species that occur during the first 5 days of zebrafish development. 
For example, the major phospholipid classes are defined by head group (e.g. 
phosphatidylcholines, phosphatidylethanolamines (PE), phosphatidylserines (PS), etc.), but each 
of these classes comprises thousands of different molecules with different types of fatty acid 
“tails.” Modern mass spectrometry technologies optimized for lipidomics can differentiate 
between individual lipid species at this level of resolution because they can precisely determine 
the mass to charge ratio (m/z) of each analyte in a mixture, and because they employ a second 
step in which the molecules are fragmented and the subsequent m/z values of these fragments is 
also determined. Complex lipids such as phospholipids are identified using m/z values calculated 
from molecular formulas and expected fragmentation patterns, and are annotated in Fraher’s 
supplemental data and other lipidomics data sets as “Head Group (FA 1/FA 2).” The most 
abundant phospholipid in animal cell membranes, for example, is phosphatidylcholine with the 
saturated 16-carbon fatty acid palmitate and the monounsaturated 18-carbon fatty acid oleate, and 
is annotated as PC(16:0/18:1). When the specific fatty acid composition of a complex lipid cannot 
be determined, only the total fatty acid carbon chain length and number of unsaturated carbon-
carbon bonds is given (e.g., PC(34:1)).  
When trends in the amounts of individual lipids in Fraher’s data set are examined, results 
suggest that changes in the phospholipid profile are consistent with an increase in membrane 
phospholipid in the larval body that is expected to occur with increasing growth. However, the 
trends in total amounts of phospholipid present in the yolk and body are skewed by changes in 
individual phospholipid species. Specifically, PC(18:2/20:4) is a major phospholipid in the body 
at the start of development and shows a large decrease by 5 dpf. However, the expected major PC 
components of cell membranes including PC(34:1) and other PCs with total chain lengths in the 
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low 30s increase over the course of larval development as expected. It is possible that longer-
chain phospholipids predominate in lipoproteins but are a minor species in cell membranes, a 
model supported by a large increase in the amount of PC 18:2/20:4 in the yolk over the course of 
development (this species is the only phospholipid in the yolk whose total molar amount 
increases over 1-5 days, though other phospholipid species increase in the yolk in terms of 
percentage of total lipid). Phospholipids containing the fatty acid arachidonic acid (20:4) are the 
precursor of eicosanoids, a class of signaling molecules with roles in regulating inflammation, 
vascular physiology, and stem cell activity (26, 27).  
This finding suggests eicosanoids as an important area of interest in the ongoing 
characterization of yolk utilization in the zebrafish.  Although the physiological implications of 
changes in individual lipids were not within the scope of this published work, the rich MS data set 
that was produced highlights the importance of examining behavior of individual lipids in studies 
of metabolism and transport. 
 
 
Complex lipid synthesis and remodeling occurs in the embryonic and larval zebrafish yolk 
The embryonic and larval zebrafish yolk is metabolically active not just in lipid transport, 
but also in the synthesis and remodeling of complex lipids, as was demonstrated through the 
injection of radioactive and fluorescently labeled lipids into the larval yolk followed by thin layer 
chromatography (TLC) analysis of the products of these metabolic tracers (23). Fatty acids 
labeled with BODIPY-FL (4,4-Difluoro-5,7-Dimethyl-4-Bora-3a,4a-Diaza-s-Indacene; a green 
fluorescent small molecule tag) or radioactive fatty acids injected into the yolk of 3 dpf larval 
zebrafish were both metabolized into complex lipids including PL, CE, and TG and transported 
throughout the developing body. Furthermore, injection of radioactive oleate showed that the yolk 
synthesizes complex lipids at the earliest stages of development, as radioactive TG and PL 
products were found in embryos injected as early as 0.75 hours post-fertilization (hpf). While the 
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rate of incorporation of radioactive oleate into each phospholipid class was consistent in embryos 
and larvae aged 0.75 hpf to 3 dpf, larvae injected at 3 dpf were the only group to synthesize 
labeled CE, and there was a large increase in the amount of radioactive TG at later stages as well 
(23). When BODIPY-C12 was injected into the yolk of 24 hpf zebrafish embryos and yolk and 
body lipids were analyzed separately by TLC 1-6 hours post injection (hpi), fluorescent complex 
lipids including TG, CE, and several unidentified species were produced in the yolk at early time 
points. Some fluorescent complex lipids were detected in the body at 6 hpi (24). (It is not known 
whether fluorescent phospholipid was synthesized in this experiment as the assay only detected 
nonpolar lipids.) Injection of fluorescent PL into the yolk at 24 hpf resulted in fluorescent 
diglyceride and unidentified complex lipid species in the yolk, but no identified products in the 
body up to 6 hpi (24). (It is not known whether fluorescent phospholipid was synthesized in this 
experiment as the assay would not have detected it.) Injection of fluorescent PL into the yolk at 
24 hpf resulted in fluorescent diglyceride and unidentified complex lipid species in the yolk, but 
no identified products in the body up to 6 hpi (24). Taken together, this and other evidence shows 
that the yolk is metabolically active throughout development and can both break down and 
synthesize complex lipids (23, 24, 28) (Table 1). 
 
  Table 1. The larval zebrafish is a versatile model system for metabolic labeling of lipids. 
Labeled Lipid Substrate Developmental Stage/ 
Delivery Method 
Assay Reported In: 
Radioactive FA 1 dpf/yolk injection TLC Miyares et al, 2014 
3 dpf/yolk injection TLC Miyares et al, 2014 
6 dpf/feeding HPLC Quinlivan et al, 2017 
Fluorescent FA 1 dpf/yolk injection TLC Fraher et al, 2016 
3 dpf/yolk injection TLC Miyares et al, 2014 
6 dpf/feeding TLC Carten et al, 2011 
HPLC Quinlivan et al, 2017 
Fluorescent PL 1 dpf/yolk injection TLC Fraher et al, 2016 
Fluorescent CE 6 dpf/feeding HPLC Quinlivan et al, 2017 
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Dietary Lipid Uptake in the Larval Zebrafish 
 
Digestion and absorption of dietary complex lipids  
 The larval zebrafish undergoes a switch from a lecithotrophic state to a free-feeding 
animal during its fifth day of development, so by the time its yolk supply is depleted it must be 
able to digest and absorb nutrients from exogenous food sources. The ability to precisely control 
timing of the first meal is an advantage of this model as processing of dietary lipids by 
enterocytes can be observed without interference from lipids absorbed from previous meals.  
Additionally, because the larva retains its transparency for several weeks after it becomes free-
feeding, it is possible to perform live imaging experiments with either single meals or ongoing 
defined diets in the same system.  
Most dietary lipid consumed by animals enters the intestine not in the form of free fatty 
acids, but in complex lipids. Dietary triglycerides, phospholipids, and cholesterol esters must be 
broken down by intestinal lipases in the lumen before the components of these molecules can 
cross the enterocyte membrane. As the fatty acids in these molecules are all linked by ester bonds, 
the intestinal lipases secreted by the exocrine pancreas are versatile and process a wide range of 
dietary lipids so that they can be absorbed (29). Following lipolysis, dietary lipid products form 
micelles in the intestinal lumen, which are emulsified in this aqueous environment by bile. The 
composition of bile varies between species and there are significant differences between teleost 
fish and humans, but its function is conserved (30, 31). 
 
Enteroendocrine cells in the intestine regulate digestion and are influenced by the 
microbiota 
As they do in mammals, enteroendocrine cells in zebrafish secrete a wide range of 
hormones including serotonin, which influences motility and appetite, and cholecystokinin 
(CCK), which stimulates gall bladder contraction and release of digestive enzymes from the 
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pancreas (32, 33). The zebrafish genome contains two CCK paralogs; ccka is expressed in the 
digestive system of adults (no data is available for larvae at this time) and both ccka and cckb are 
expressed in the brain starting at 24 hpf (34, 35). In mammals, CCK promotes lipid digestion by 
stimulating the gall bladder to secrete bile, but does not increase lipase activity (36, 37).  
Similarly, larval zebrafish treated with a CCK receptor antagonist show reduced protease activity 
while intestinal phospholipase activity is unaffected (29). Enteroendocrine cells expressing 
serotonin begin to appear in the larval zebrafish intestine at 5 dpf. They may be detected by 
immunohistochemistry for serotonin, and are distinguished from the enteric neurons (which also 
express serotonin) by their shape and location in the epithelium. By 8 dpf, 10-18 enteroendocrine 
cells per larva may be observed in the distal intestine (posterior to the swim bladder) (14). A 
notable difference is that the larval zebrafish intestine does not have crypts, where 
enteroendocrine cells would be located in mammals. 
 The intestinal microbiota is required for normal enteroendocrine cell development. In 
germ-free larval zebrafish, 0-6 enteroendocrine cells were observed at 8 dpf (the total number of 
cells in the distal intestinal epithelium did not vary between germ-free and conventional groups). 
Larvae raised germ-free until 5 dpf, and then colonized with the conventional microbiota, 
developed normal numbers of enteroendocrine cells, suggesting that the yet-unidentified signal 
from the microbiota that promotes enteroendocrine cell development is not required before 5 dpf. 
Higher gut motility was observed in zebrafish larvae raised germ-free, suggesting a possible 
connection to digestive problems (including irritable bowel disease) observed in humans when 
the gut microbiota is disrupted (14). The lower number of serotonin-positive cells could explain 
this physiological effect as serotonin regulates gut motility in humans (32). 
 
The intestinal microbiota influences dietary lipid uptake 
The bacterial population of the intestine also plays an important role in dietary lipid 
uptake and metabolism. Fermentation by the gut microbiota allows host animals to utilize dietary 
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plant polysaccharides that would otherwise be indigestible by converting them to metabolizable 
short-chain fatty acids and monosaccharides (38). Multiple studies over the last decade have 
shown effects of changes in composition of the gut microbiota on adiposity, serum lipids, and 
tissue lipids in mammals. However, determining mechanisms by which bacteria may cause global 
changes in vertebrate host physiology has been difficult as the composition of the gut microbiota 
also changes in response to changes in diet (39). The larval zebrafish model was recently used to 
investigate aspects of the relationship between gut bacteria and lipids involving processes other 
than short-chain fatty acid synthesis: when larvae raised germ-free were given a high-fat meal 
labeled with fluorescent fatty acids, less fluorescence accumulated in the intestinal epithelium 
when compared with conventionally raised larvae, showing that at least some members of the 
microbiota are necessary to promote uptake of dietary lipids. Monoassociated larvae (larvae 
raised germ-free and then inoculated with a single bacterial species) colonized with the 
Firmicutes strain Exiguobacterium sp. were used to demonstrate that this bacterial strain alone 
was sufficient to promote intestinal fatty acid uptake to a point where fluorescence could be 
observed in extra-intestinal tissues. Furthermore, experiments using conditioned media from this 
strain and two others also revealed significant increases in enterocyte lipid droplet number over 
untreated germ-free larvae, suggesting that a factor secreted by these species is involved in 
promoting dietary lipid uptake (40). The exact mechanism for this host-microbe relationship is 
currently uncharacterized, as is the evolutionary advantage of promoting host lipid uptake for 
these microbial species. 
 
Lipid transport into enterocytes 
 Dietary lipids are imported from the intestinal lumen across the apical enterocyte 
membrane by several different mechanisms depending on their class. After complex lipids 
(including both glycerolipids and cholesterol esters) are digested to yield fatty acids, 
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monoglycerides, and/or lysophospholipids, these products may cross membranes by a variety of 
transport processes conserved among zebrafish and mammals. 
 Cholesterol is taken up by enterocytes by a mechanism that requires the Niemann-Pick 
C1-Like 1 (NPC1L1) transport protein (41, 42). This membrane-associated protein is located at 
the luminal border of enterocytes and is translocated to an intracellular compartment when cells 
are exposed to cholesterol; current models postulate a clathrin-dependent endocytic mechanism in 
which NPC1L1 is internalized along with a cholesterol cargo, which then moves through 
endosomes to the endoplasmic reticulum where it can be packaged into membranes or used to 
synthesize cholesterol ester (43, 44). NPC1L1 is encoded in the zebrafish genome, and several 
lines with point mutations in this gene have been created through the Sanger Institute Zebrafish 
Mutation Project (45). Ezetimibe, an inhibitor of NPC1L1-mediated cholesterol absorption that is 
used to treat hypercholesterolemia in humans, also blocks dietary cholesterol absorption in larval 
zebrafish (46-48). This creates an opportunity to use the zebrafish model to study physiological 
effects of modulating metabolic availability of a single component of a mixed-lipid diet. 
Regulation of NPC1L1 activity remains largely uncharacterized, although there is evidence from 
studies in humans given statins (inhibitors of cholesterol synthesis) that NPC1L1 expression 
levels increase in response to low intracellular cholesterol levels, suggesting that there may be an 
unidentified genetic mechanism that regulates NPC1L1 expression that could counteract the 
effects of statins by upregulating import of dietary cholesterol (49). 
 Fatty acid transfer proteins (FATPs) are a family of integral membrane proteins that 
facilitate transport of fatty acids into cells, including transport of dietary fatty acids into 
enterocytes. FATPs act in concert with acyl-coA synthetases (ACSs), which activate the newly 
imported fatty acids so that they are ready to form ester bonds and be incorporated into complex 
lipids (50, 51). There is evidence from mammalian and cell culture models that both the FATP 
and ACS families play roles in regulating preferential uptake of some dietary fatty acids over 
others, and the partitioning of dietary fatty acids among complex lipids (51, 52). The zebrafish 
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genome encodes 9 ACSL (ACSs specific to long-chain fatty acids, the type of fatty acid most 
abundant in animals including zebrafish) gene paralogs in six families. Expression of this class of 
genes is ubiquitous, with proteins corresponding to seven of nine paralogs detectable in the adult 
by Western blot in most tissues including the gut (53). Expression of ACSL genes in the larva is 
more regionalized: in the acsl1 family, acsl1b mRNA is detectable in the YSL and gut in early 
larval stages. The acsl1a paralog is not expressed in the YSL and no expression data is available 
for early gut development (54). (Only acsl1a is expressed in the gut in adults (53).) Acsl4a 
mRNA is present in both the YSL and the larval gut (55). Expression of acsl4b and acsl5 is 
detectable in the YSL but expression data is not available from larval stages after the gut has 
begun to develop (54) (Figure 2). Expression data is unavailable for the other acsl paralogs at any 
embryonic or larval stage, but what is known about expression of acsl genes in this model 
suggests potential division of function among paralogs similar to that suggested by regionalized 
apolipoprotein gene expression.  
Compared with the ACSs there is far less coverage of zebrafish fatty acid transfer 
proteins in the current literature. As of now no studies of FATP function in this model system 
have been published and only one genomic sequence is annotated as a FATP in the Ensembl 
database; FATP3/ACSVL3/SLC27A3 (with 7 paralogs, all annotated as members of solute carrier 
family 27 (slc27)).  The other six putative FATP paralogs are annotated as SLC27A1A and B 
(both with 65% protein sequence identity to human SLC27A1/FATP1/ACSVL5 (a mitochondrial 
long-chain FATP (56)), using the NCBI protein BLAST tool)), SLC27A2A (47% protein 
sequence identity to human SLC27A2/FATP2/ACSVL1), SLC27A2B (55% protein sequence 
identity to human SLC27A2/FATP2/ACSVL1), SLC27A4 (70% protein sequence identity to 
human SLC27A4/FATP4/ACSVL4), and SLC27A6 (57% protein sequence identity to human 
SLC27A6/FATP6/ACSVL2). The chromosomal locations of all of these putative fatp genes are 
conserved between the human and zebrafish genomes (syntenic analysis by ZFIN). 
$*!
Figure 2. Acetyl-CoA synthetases are expressed in the larval zebrafish YSL and 
intestine. A) In situ hybridization reveals expression of acsl1b, acsl4b, and acsl5 in the YSL 
at 24 hpf, and acsl1b in the developing gut at 2 dpf. Adapted from Thisse et al, 2004. B) 
acsl4a is expressed in the gut and central nervous system (cns) of the 4dpf larval zebrafish, 
and in the YSL at 24 hpf and earlier. Reprinted from Miyares et al, 2013, Figure S1 E.          
C) fatp4/acsvl4 is expressed in the gut (especially the anterior bulb) of the 5 dpf larval 
zebrafish. Adapted from Thisse et al, 2005.
	 18	
Zebrafish SLC27A2A is expressed in the adult liver (57), and SLC27A4 is expressed in the 
anterior gut at 5 dpf (58) (Figure 2). No expression data is available for other adult organs, earlier 
larval stages, or the other putative FATPs at this time. However, as FATP4 is the primary fatty 
acid transporter on the apical brush border of human enterocytes, the similarity in expression 
between zebrafish and humans supports the larval zebrafish as a model in the investigation of 
FATP function in dietary fatty acid absorption (59).  
The relative contributions of FATP4, other membrane-associated fatty acid binding 
proteins, and passive diffusion to uptake of dietary fatty acids by enterocytes in larval zebrafish 
are not known. A recent review proposes a model in which the transmembrane receptor protein 
CD36, Caveolin 1 (Cav1), and FATP4 all act as fatty acid transporters at the enterocyte brush 
border, and in which passive diffusion of long-chain fatty acid salts across the enterocyte 
membrane plays a major role in adsorption (60). Larval zebrafish express CD36 and Cav1 in the 
intestine as well as FATP4, and therefore present an opportunity to apply live whole-animal 
imaging tools toward investigations of the roles of each of these proteins in dietary fatty acid 
processing (61, 62). (Unlike mammals, Cav1 is located on the basolateral membrane of 
enterocytes in zebrafish and not at the brush border (62).) In sum, despite tight conservation of 
FATP genes and their intestinal expression throughout the vertebrates, their physiological role in 
the intestine remains unclear. 
  
Lipid processing in enterocytes for storage and export 
Fatty acids taken up by enterocytes are re-packaged into complex lipids at the 
endoplasmic reticulum, and are subsequently stored in enterocyte lipid droplets or directed to 
lipoprotein synthesis for export. Lipid droplets are composed primarily of triglycerides and 
cholesterol esters in the interior, and bounded by a phospholipid monolayer with associated 
proteins such as perilipins (63). Though the mechanisms by which lipid droplets grow and shrink 
are well characterized, the regulation of lipid droplet size and number in various tissues is not as 
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well understood, and most current research efforts focus on adipose and hepatic lipid droplets 
(64). As the intestine is not a site of long-term lipid storage in vertebrates including larval 
zebrafish, enterocyte lipid droplets are highly dynamic, temporary structures that respond with 
high sensitivity to the nutritive state of the animal. This property combined with the relative ease 
of live imaging in the larval zebrafish intestine makes for an ideal system for the study of lipid 
droplet dynamics and regulation. When 5 dpf larvae are fed a high-fat/high-cholesterol meal of 
chicken egg yolk, both the average lipid droplet number per enterocyte and total area of the cell 
covered by lipid droplets increase significantly by 1 hour post-feeding. Lipid droplet number 
peaks at 1 hour and then gradually decreases, while total lipid droplet area is maintained up to 
three hours following the meal, suggesting that smaller lipid droplets fuse as they mature (65). 
The gut microbiota also influence enterocyte lipid droplet number and size. Intestinal lipid 
droplets are both larger and more numerous in conventionally-raised larvae after feeding than in 
germ-free larvae. Furthermore, conditioned media from a Firmicutes bacterial strain found to 
promote dietary fatty acid uptake and export to the liver was sufficient to increase enterocyte lipid 
droplet number but not the average lipid droplet size (40). These results have begun to reveal the 
diverse mechanisms by which different members of the gut microbiota influence lipid droplet 
dynamics and dietary lipid metabolism. 
Lipoproteins are essential for the export of the products of dietary lipid from enterocytes 
into the circulation. Expression and function of apolipoproteins in the zebrafish is similar to that 
observed in mammals; at least one paralog from each of the ApoA-I, ApoB, ApoE, and ApoA-IV 
families is expressed in the larval zebrafish intestine (16). There is evidence that division of 
apolipoprotein function among organs is regulated by different mechanisms that achieve the same 
end in zebrafish and mammals: while different variants of ApoB are produced in the mammalian 
intestine and liver via RNA editing, larval zebrafish produce mRNA for the ApoB paralog b.1 in 
the intestine and liver and ApoBb.2 in the liver only. Similar compartmentalization of paralog 
expression between the liver and intestine is observed in the other apolipoprotein families as well 
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(16) (Figure 3). Intestinal lipid accumulation in animals treated with an MTP inhibitor shows that 
as in the larval zebrafish yolk, availability of functional ApoB in necessary for normal rates of 
lipid export from the intestine, and that enterocyte lipid droplets are the destination of excess 
dietary fatty acids when export is slowed (66-68). The MTP inhibitor lomitapide is effective in 
larval zebrafish (65). It has also been observed that in mammals as the dietary fat content 
increases, chylomicron number reaches a plateau but average chylomicron size continues to 
increase, suggesting that apolipoprotein expression is the limiting factor in the rate of lipid export 
from the intestine (69). 
 
Total lipid biochemistry of the larval zebrafish reveals global effects of diet on lipid 
composition, and facilitates metabolic labeling studies  
The larval zebrafish intestine is not only an excellent model for the study of lipid droplet 
and lipoprotein packaging, but also a site of differential channeling of dietary fatty acids 
depending on their chemical properties. The amenability of this model to biochemistry due to the 
ease of obtaining large numbers of embryos and larvae and performing lipid extractions from 
them, combined with the transparency of the larva, provides an opportunity unique among 
vertebrates to perform live imaging and metabolic labeling experiments in parallel using the same 
fluorescent lipid reagents. Additionally, the whole-body lipid composition of the larval zebrafish 
is highly sensitive to changes in diet: the triglyceride content of the 6 dpf larva increases 10-fold 
24 hours after a single high-fat meal (compared with a standard low-fat diet, and allowing time 
for the intestinal lumen to clear). Working at developmental stages before adipose tissue appears 
(~14 dpf) avoids signal to noise problems that may occur when the neutral lipid stored in adipose 
is included in the whole-body lipid profile. Also, at these early developmental stages examination 
of dietary lipid processing in the intestine can be isolated from potential regulatory influences 
from adipose tissue. 
%$!
Figure 3. Zebrafish apolipoprotein genes are expressed in the larval digestive system.  In 
situ hybridization reveals expression of 10 of the 11 zebrafish apolipoprotein genes in the 
apoB, apoA-IV, apoE, and apoA-I families in the liver and/or intestine of the 6 dpf larva. 
Dissected intestines probed for apoA-Ia are shown, and the gut of a larva probed for apoA-1b 
is magnified below the image of the whole larva. L = liver, I = intestine. Adapted and 
reprinted from Otis et al, 2015, Figures 2-5, under a CC-BY license. 
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 Though it was beyond the scope of our recent metabolic labeling study (70), the 
biochemical techniques described therein could be applied to later-stage larvae in order to 
examine potential crosstalk between adipose tissue and the enterocytes that could influence 
dietary lipid partitioning. We have also developed methods for using fluorescent fatty acids as 
metabolic labels in the context of standard and lipid-enriched diets in larval zebrafish (Table 1). 
In addition to exploring the metabolic labeling potential of fluorescent lipids whose product 
profiles were not previously described, we have also applied HPLC with charged aerosol (total 
lipid detection) and fluorescence detection to obtain a greater depth of information than previous 
studies using fluorescent TLC (28). Initial findings (described in Chapter 2) indicate that the 
partitioning of saturated fluorescent fatty acids among complex lipid classes varies with carbon 
chain length, the total fat and cholesterol content of the diet, and the type of fluorescent tag (70). 
Metabolic labeling with fluorescent fatty acids in the context of lipid metabolism by the larval 
zebrafish is summarized in Figure 4. 
Potential mechanisms regulating the rate of lipid export from the intestine beyond 
lipoprotein levels, the regulation and physiological effects of the size of enterocyte lipid droplets, 
and the channeling of newly absorbed dietary fatty acids into the different classes of complex 
lipids are currently largely uncharacterized. The optically clear and genetically tractable larval 
zebrafish model presents an ideal system in which to investigate these questions relating to 




Figure 4. Metabolic labeling with fluorescent fatty acids is performed in the context of 
zebrafish development, yolk absorption, and dietary lipid metabolism. Fluorescent fatty 
acids (BODIPY FL-C12 depicted) are trafficked and metabolized along with native yolk or 
dietary lipids when delivered to the developing zebrafish by yolk injection or feeding. LD = 
cytoplasmic lipid droplet, LP = lipoprotein, VLDL = very low-density lipoprotein. Embryo 
and larva illustrations adapted from Miyares et al, 2014. 
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Fluorescent lipids are important tools for live imaging in cell culture and animal models, 
yet their metabolism has not been well-characterized. Here we describe a novel combined HPLC 
and LC-MS/MS method developed to characterize both total lipid profiles and the products of 
fluorescently labeled lipids. Using this approach we found that lipids labeled with the fluorescent 
tags BODIPY FL, BODIPY(558/568), and TopFluor are all metabolized into varying arrays of 
polar and nonpolar fluorescent lipid products when they are fed to larval zebrafish. Quantitative 
metabolic labeling experiments performed in this system revealed significant effects of total 
dietary lipid composition on fluorescent lipid partitioning. We provide evidence that cholesterol 
metabolism in the intestine is important in determining the metabolic fates of dietary fatty acids. 
Using this method we found that inhibitors of dietary cholesterol absorption and esterification 
both decreased incorporation of dietary fluorescent fatty acids into cholesterol esters, suggesting 
that cholesterol ester synthesis in enterocytes is primarily responsive to the availability of dietary 
cholesterol. These results are the first to comprehensively characterize fluorescent fatty acid 
metabolism and to demonstrate their utility as metabolic labeling reagents, effectively coupling 






When dietary fatty acids are absorbed by intestinal enterocytes, those that are not 
oxidized are incorporated into complex lipids (lipid molecules containing more than one acyl 
chain and/or sterol group) including phospholipids, triglycerides, and cholesterol esters. This 
process involves a network of transporters, enzymes, and cellular components, the roles and 
regulation of which are still being characterized (71-73). The processes by which dietary fatty 
acids are distributed among various complex lipid classes and how assembly of complex lipids 
from dietary fatty acids may be influenced by other nutrients including dietary cholesterol are not 
fully understood.  
To investigate dietary fatty acid metabolism in a quantitative manner, it was necessary to 
develop an animal model wherein individual fatty acids could be studied in the context of the 
digestion and absorption of a physiologically relevant mixed-lipid diet. While cell culture is a 
well-established model system for the study of lipid metabolism, it cannot replicate the digestive 
and metabolic physiology of a whole vertebrate animal with a functional liver, intestine, pancreas, 
and microbiota such as the larval zebrafish (15, 40, 74-79). An additional strength of this model is 
that live imaging and biochemical experiments may be performed in parallel using the same 
fluorescent lipid reagents and experimental system (2, 23, 24, 28, 29, 48, 80-83). Many 
publications using fluorescent lipid reagents did not examine the metabolism of these labels (with 
some asserting that some or all fluorescent fatty acids are not metabolizable (84-86)), but prior 
work has shown that BODIPY® FL (4,4-Difluoro-5,7-Dimethyl-4-Bora-3a,4a-Diaza-s-
Indacene)-labeled fatty acids may be esterified and incorporated into products including 
phospholipids, triglycerides, and cholesterol esters (28, 87-91). However, with the exception of 
two HPLC-Fluorescence profiles of the phospholipid products of BODIPY FL-C12 (BODIPY 
FL-dodecanoic acid) (87, 88), all published characterization of the metabolic products of 
fluorescent lipids has been performed with thin layer chromatography (TLC), which unlike HPLC 
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does not resolve individual lipid species within each class. For this study we developed a novel 
total-lipid HPLC method that allowed the complex lipid product profiles of BODIPY FL-labeled 
fatty acids and other fluorescent lipids commonly used in imaging experiments to be described in 
detail, and facilitated investigation of the role of nutritional context in how fluorescent lipids are 
metabolized. 
Emulsification of fluorescent fatty acids into chicken egg yolk (a high-fat/high-
cholesterol meal relative to standard larval fish diets) has been shown to promote their 
metabolism when they are fed to larval zebrafish, but how the nutritional context in which 
fluorescent lipids are delivered regulates their partitioning has not been characterized (28). There 
is evidence from mammalian models for interaction between the dietary cholesterol and fatty acid 
uptake and metabolism pathways: cholesterol esters are synthesized in enterocytes, and dietary 
long-chain fatty acids enhance dietary cholesterol uptake in rats, but the mechanisms for this 
interaction remain unknown (30, 31(92, 93). We applied our novel fluorescent lipid profiling 
method to examine the effect of the metabolic availability of dietary cholesterol on intestinal 
cholesterol ester synthesis in order to better understand the role of cholesterol regulation 
mechanisms in dietary fatty acid metabolism.  
In this study we describe total lipid profiles of the 6-dpf (days post-fertilization) larval 
zebrafish after both low-fat/low-cholesterol and high-fat/high-cholesterol meals, and the 
fluorescent product profiles synthesized from the most commonly used commercially available 
fluorescent lipids when they are fed to larval zebrafish in several different diets. This thorough 
characterization of the metabolism of fluorescent lipids will greatly expand the depth of 
physiological information that may be gained from using these reagents in well-established live 
fluorescent imaging methods. We also demonstrate a novel application of fluorescent fatty acids 
as metabolic labeling reagents by showing that pharmaceutical manipulations of intestinal 
cholesterol metabolism result in significant changes in dietary fluorescent fatty acid partitioning, 
suggesting coupling between dietary cholesterol uptake and esterification.  
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Materials and Methods 
 
Zebrafish 
Embryos were collected from group matings of wild-type (AB) Danio rerio (zebrafish) 
and raised to the 6 days-post-fertilization (dpf) larval stage at 28oC on a 14:10 on:off light cycle 
in embryo media. All experiments with zebrafish (protocol #139) were approved by the Carnegie 
Institution Department of Embryology IACUC.  
 
Food Preparation and Feeding 
The fluorescent fatty acids BODIPY® FL-C5 (4,4-Difluoro-5,7-Dimethyl-4-Bora-3a,4a-
Diaza-s-Indacene-3-Pentanoic Acid; Thermo Fisher Scientific), BODIPY® FL-C12 (4,4-
Difluoro-5,7-Dimethyl-4-Bora-3a,4a-Diaza-s-Indacene-3-Dodecanoic Acid; Thermo Fisher 
Scientific), BODIPY® FL-C16 (4,4-Difluoro-5,7-Dimethyl-4-Bora-3a,4a-Diaza-s-Indacene-3-
Hexadecanoic Acid; Thermo Fisher Scientific), BODIPY®(558/568)-C12 (4,4-Difluoro-5-(2-
Thienyl)-4-Bora-3a,4a-Diaza-s-Indacene-3-Dodecanoic Acid; Thermo Fisher Scientific), and 
TopFluor®-C11 (dipyrrometheneboron difluoride undecanoic acid; Avanti Polar Lipids) were 
administered to larval zebrafish in HF/HC (high-fat/high-cholesterol) meals: Solutions of 5% 
chicken egg yolk liposomes containing 4 µg/mL fluorescent fatty acid were prepared as 
previously described (28). Larval zebrafish (6 dpf) were immersed in these solutions for 2 hours, 
protected from light in a shaking incubator at 30oC and 30 rpm. After feeding, larvae were rinsed 
in fresh embryo media and screened for full intestines under a stereomicroscope. Larvae that had 
eaten were maintained in embryo media at room temperature for a 4-24 hour chase period 
(measured from the start of feeding) depending on the experiment. Samples of 10-100 pooled 
larvae were collected for lipid extraction and stored dry at -80oC. 
To compare the metabolism of BODIPY FL-C12 and palmitate, larvae were fed 
equimolar amounts of BODIPY FL-C12 (9.56 µM) and palmitic acid (0.85 µM 3H-palmitic acid 
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and 8.71 µM unlabeled palmitic acid) in a HF/HC meal for two hours at 25oC and 30 rpm. Larvae 
were maintained at 25oC in embryo media for 18 hours, and then samples of 25 larvae each were 
taken for lipid extraction. 
For experiments in which lipids were extracted from larval zebrafish intestines, larvae 
were anesthetized in tricaine (3-amino benzoic acid ethyl ester) and mounted in 3% 
methylcellulose. Intestines were removed using tungsten wire dissecting tools prepared according 
to published methods (94), and stored in lipid extraction buffer (1 mM EDTA, 20 mM Tris-Cl) at 
-80oC. Alternately, larvae could be fixed 24-72 hours at 4oC in 4% paraformaldehyde, transferred 
to PBS, and then dissected. No differences in lipid profiles as analyzed by HPLC-CAD were 
observed between fixed and unfixed samples. All data shown is from lipid extracts of unfixed 
larvae. 
Preparation of LF/LC (low-fat/low-cholesterol) and LF/HC (low-fat/high-cholesterol) 
foods with fluorescent lipids was adapted from published methods (83).  For the LF/LC diet, 2.5 
nmol fluorescent lipid (BODIPY FL-C12, BODIPY®(558/568)-C12, Cholesterol BODIPY® FL-
C12 [Thermo Fisher Scientific], or Cholesterol BODIPY®(576/589)-C11 [cholesterol 4,4-
difluoro-5-(2-pyrrolyl)-4-bora-3a,4a-diaza-s-indacene-3-undecanoate; Molecular Probes, 
discontinued]) was diluted in 0.5 mL diethyl ether, combined with 0.1 g Sera® Micron larval fish 
food, and solvents were allowed to evaporate. For LF/HC diets, 4 mg cholesterol (4% w/w) was 
added as well. Larval zebrafish (5 dpf) were fed LF/LC or LF/HC meals twice per day for two 
days at 25oC, and then LF/LC or LF/HC meals with fluorescent lipid for three days at 25oC 
protected from light. Food was then withdrawn and samples of 20-75 larvae were taken after an 
overnight chase to allow larvae to excrete any unabsorbed food remaining in the intestinal lumen. 





Sample Preparation, HPLC, and Data Analysis 
Lipids were extracted from frozen larvae samples by a Bligh-Dyer procedure, dried under 
vacuum, and resuspended in 100 µL HPLC-grade isopropanol per sample as the HPLC injection 
solvent. The components of each sample were separated and detected by an HPLC system using a 
LPG-3400RS quaternary pump, WPS-3000TRS autosampler (maintained at 20.0oC), TCC-
3000RS column oven (maintained at 40.0oC), Accucore C18 column (150 x 3.0 mm, 2.6 µm 
particle size), FLD-3100 fluorescence detector (8 µL flow cell maintained at 45.0oC), and Dionex 
Corona Veo charged aerosol detector (CAD) (all from Thermo Fisher Scientific). Component 
peaks were resolved over an 80 min time range in a multistep mobile phase gradient as follows: 
0-5 min = 0.8 mL/min in 98.0% mobile phase A (methanol-water-acetic acid, 750:250:4) and 
2.0% mobile phase B (acetonitrile-acetic acid, 1000:4), 5-35 min = 0.8-1.0 mL/min, 98.0-30% A, 
2.0-65.0% B, and 0-5.0% mobile phase C (2-propanol), 35-45 min = 1.0 mL/min, 30%-0% A, 
65.0%-95.0% B, and 5.0% C, 45-73 min = 1.0 mL/min, 95.0-60.0% B and 5.0-40.0% C, and 73-
80 min = 1.0 mL/min, 60.0% B, and 40.0% C. (HPLC-grade acetic acid and 2-propanol were 
purchased from Fisher Scientific and HPLC-grade methanol and acetonitrile were purchased from 
Sigma-Aldrich.) The following adjustments were made to the solvent gradients for better 
separation of nonpolar products of BODIPY FL-C5 and BODIPY FL-C12: In the “B-C5” 
instrument method, the flow rate was decreased to 0.5 mL/min at 40-80 minutes, and in the “B-
C12” method the flow rate was decreased to 0.5 mL/min at 45-80 minutes. Between 5 and 99 µL 
were injected per sample to produce peak shapes suitable for quantitation. For HPLC-
fluorescence, the following excitation and detection wavelengths were used: 576/596 nm for 
products of cholesterol BODIPY(576/598)-C11, 558/578 nm for products of BODIPY(558/568)-
C12, and 488/512 nm for products of BODIPY FL(503/512) and TopFluor-labeled lipids. It was 
not possible to use excitation and detection settings that matched the maxima for each BODIPY-
lipid because for the FLD-3100 fluorescent HPLC detector these settings must be at least 20 nm 
apart. Optimal fluorescent detector settings were determined empirically (data not shown). 
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Chromatographic peaks produced by cholesterol as well as several fluorescent and non-
fluorescent cholesterol esters were identified by comparison with standards (Sigma-Aldrich and 
Thermo Fisher Scientific). Non-cholesterol-containing lipids were identified and quantitated by 
mass spectrometry as described below. Additionally, acetone precipitation (adapted from (95)) 
was performed on some samples prior to HPLC so that fluorescent analytes that could not be 
precisely identified by mass spectrometry could be classified as polar or nonpolar lipids. 
Quantitation of lipid species was performed using Chromeleon 7.2 (Thermo Fisher Scientific, 
Germering, Germany). Peak baselines were drawn manually and areas were determined 
automatically. Further data analysis (where applicable) was performed using Microsoft Excel 
with the StatPlus package. 
To compare the metabolic products of BODIPY FL-C12 and 3H-palmitic acid, lipids 
extracted from larval zebrafish fed these fatty acids simultaneously as described above were 
subjected to HPLC-Fluorescence analysis using the “B-C12” method, after which the eluent was 
collected in 1-minute increments (Model 2110 Fraction Collector, Bio-Rad Laboratories) and 
radioactivity was quantitated using a liquid scintillation counter (Tri-Carb 2810 TR Liquid 
Scintillation Analyzer, Perkin-Elmer; 3a70b scintillation fluid, Research Products International 
Corp.). Fluorescent chromatograms were quantitated in Chromeleon 7.2 by simulated fraction 
collection: a flat baseline was drawn from zero to 80 minutes and each 1-minute area was 
assigned as a “peak” by placing a delimeter perpendicular to the baseline.  
 
LC-MS and Data Analysis 
For LC-MS experiments, chromatography was performed using the procedure and 
equipment described above, with eluent directed to a mass spectrometer in place of the charged 
aerosol detector after exiting the fluorescence detector. High-resolution accurate-mass 
spectrometry data were recorded on a Q Exactive Plus mass spectrometer (Thermo Fisher 
Scientific, Bremen, Germany) equipped with a heated electrospray-ionization probe (HESI-II). 
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Data were acquired in positive and negative polarity with the following source parameters: spray 
voltage, 3.5 kV for positive polarity and 3.2 kV for negative polarity; sheath gas flow, 70 
(arbitrary units); auxiliary gas flow, 25 (arbitrary units); sweep gas flow, 1 (arbitrary units); 
auxiliary gas heater temperature, 400°C; capillary temperature, 285°C; S-Lens RF level, 45 %. 
The instrument was operated with external mass calibration without use of a lock mass. Mass 
spectra were recorded in data-dependent MS/MS mode as a Top-12 experiment with the 
following acquisition settings: mass resolution, 140,000 for full-MS and 17,500 for MS2; full-MS 
scan range, 200-1600 Da; quadrupole isolation window, 1.2 Da; normalized collision energy, 
stepped 20-30-40%; exclusion mass list, 200 entries (created individually for each polarity mode 
from injection solvent blank runs). Data acquisition and quantitation was performed using 
Xcalibur (version 3.0.63, Thermo Fisher Scientific), and identification of non-fluorescent lipid 
analytes was performed with LipidSearch (version 4.0, MKI, Tokyo, Japan). Fluorescent lipids 
were identified manually by using Xcalibur to search for analyte peaks containing boron, as this 
element lends a unique isotopic signature to the BODIPY FL fluorescent tag. The two most 
common boron isotopes, 10B and 11B, exist naturally and in BODIPY FL-fatty acids (verified 
experimentally using standards; data not shown) in a 1:10-1:4 ratio and have a Δm/z of 0.9964 
amu. Pairs of analytes that fit this signature, eluted at the same retention time, and were specific 
to a single fluorescent HPLC peak were identified as specific BODIPY-lipids by comparing 
experimental m/z to the expected m/z of each of a range of potential products of BODIPY FL-C5, 
-C12, and -C16. Expected m/z was calculated from molecular formulas using the Lipid MAPS® 
exact mass tool at http://www.lipidmaps.org/tools/structuredrawing/masscalc.php. 
 
Confocal Imaging 
 Larval zebrafish were fed both BODIPY FL-C12 and BODIPY(558/568)-C12 emulsified 
in 5% chicken egg yolk at 4 µg/mL for two hours at 30o C as described above, and then 
transferred to fresh embryo media and incubated at room temperature. Live confocal imaging was 
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performed 6 hours after removal of larvae from the HF/HC food (Figure 4). Larvae were 
anesthetized with tricaine and live mounted for imaging in 3% methylcellulose under a coverslip 
at room temperature. Fluorescent images were acquired with a Leica TCS SP5 II confocal 
microscope equipped with an Argon laser, Leica 63x/1.4 oil-immersion objective, and Leica 
Application Suite Advanced Fluorescence 2.7.3.9723 image acquisition software. Images were 




Larval zebrafish were treated with ezetimibe using a protocol adapted from published 
methods which demonstrated that ezetimibe blocks dietary cholesterol uptake in larval zebrafish 
(65, 96): at 5 dpf larvae were immersed in a 5 µM ezetimibe (SCH58053, Santa Cruz Biotech) 
and 0.1% ethanol (vehicle) solution and maintained at 25.0oC for 20 hours. While being fed 
experimental diets, larvae were treated with 10 µM ezetimibe. Following meals, larvae were 
returned to a 5 µM ezetimibe solution until samples were taken for lipid extraction. 
A similar protocol for treatment of larval zebrafish with an ACAT inhibitor (CAY10486, 
N-[3-(4-hydroxyphenyl)-1-oxo-2-propenyl]-L-phenylalanine methyl ester, Cayman Chemical) 
was developed from a published method for ACAT inhibition in embryos (23). Beginning at 5 
dpf, larvae were immersed in a 100 µM ACAT inhibitor and 0.5% DMSO (vehicle) solution and 
maintained at 25.0oC for 20 hours. This ACAT inhibitor concentration was maintained during and 





A comprehensive total lipid HPLC method facilitates detection and quantitation of all 
classes of lipids in a single sample 
In order to obtain the greatest possible depth of information from metabolic labeling with 
dietary fluorescent fatty acids, it was crucial to understand the lipidomic context surrounding 
these metabolic tracers. Lipid profiling by HPLC with various detection methods is a well-
established practice (97-103) that allows for relatively high-throughput and low-cost experiments 
(when compared with LC-MS). However, precise identification of complex lipids resolved by 
HPLC using standards is often impractical, as there are thousands of possible unique 
phospholipid species and tens of thousands of possible triglycerides. For this reason lipid 
researchers often turn to MS-based lipidomics, which can provide precise identification (if high 
resolution, accurate mass detection methods are used) and quantitation of complex lipids, but 
often at the cost of limiting the number of samples and replicates that may be analyzed. Here we 
describe a combined HPLC-CAD and LC-MS workflow in which a lipidomic data set obtained 
from a short series of LC-MS experiments is used to interpret results from a large number of 
HPLC experiments, retaining the high-throughput/low-cost advantage of HPLC while enhancing 
the type and quality of data that may be obtained from HPLC lipidomics. A multistep gradient 
HPLC procedure for analysis of the larval zebrafish lipidome was designed to resolve the 
components of a mixed sample consisting of lipids of a wide range of molecular weights, degrees 
of polarity, and degrees of saturation. A single LC-MS/MS experiment (n = 3 biological 
replicates) was then performed using the chromatography component of our established HPLC 
method in order to identify the specific lipid contents of each analyte peak detected by HPLC-
CAD/Fluorescence (Figure 1). The lipidomic data set this experiment yielded (Supplemental 
Table S1) could then be used to interpret the results of any HPLC experiment performed with the 
same instrument method. Cholesterol and most cholesterol esters were not detected by the MS 
&'!
method we employed, but were detected by HPLC-CAD and identified by comparison with 
purchased standards (Sigma-Aldrich). The composition of each lipid peak detected by HPLC-
CAD is summarized in Supplemental Table S2. Total fatty acid composition of larval zebrafish 
was similar in groups fed a single LF/LC or HF/HC meal, despite differences in dietary fatty acid 
composition. Fatty acid composition analysis of only the triglycerides shows that oleic acid is 
enriched 2.3-fold and linoleic acid is enriched 1.9-fold in the triglycerides of larvae fed a HF/HC 
meal (versus LF/LC), and that DHA is enriched 6.2-fold in larvae fed a LF/LC meal (versus 
LF/HC) (Supplemental Table S3). This is consistent with differences in dietary fatty acid 
composition, where the HF/HC diet is 35% oleic acid (vs. 14% in LF/LC) and 16.5% linoleic acid 
(vs. 9% in LF/LC), and the LF/LC diet is 8.6% DHA (vs. 0.5% in HF/HC). Less prevalent species 
enriched in the triglycerides of LF/LC-fed larvae (versus larvae fed the HF/HC meal) include 
20:5, 16:1, and 20:4. No other changes in fatty acid composition greater than 1.5-fold were 
observed between the HF/HC and LF/LC groups in fatty acid species accounting for >0.3% of the 
total in triglycerides. 
HPLC-CAD analysis reveals that the whole-body lipid content of larval zebrafish is 
enriched in a variety of triglycerides following a single HF/HC meal, while other   
Figure 1 (next page). A combined HPLC-CAD and LC-MS/MS workflow for total 
lipid profiling of larval zebrafish. Once an HPLC method was established that resolved 
lipids of all classes present in larval zebrafish, the instrument was temporarily reconfigured 
to route sample flow to a quadrupole-Orbitrap mass spectrometer instead of the charged 
aerosol detector. Data obtained from a series of LC-MS/MS experiments with exact mass 
detection was then used to identify the components of peaks observed by HPLC-
CAD/fluorescence. Through this combined workflow, peak composition data from a single 
LC-MS/MS experiment greatly enhances the depth of information that may be obtained 
from all future HPLC experiments performed using the same instrument method.  
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Figure 1.  
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lipid species are unchanged (Figure 2). The triglyceride content of larval zebrafish fed a HF/HC 
meal is increased on average 10-fold over larval zebrafish fed a LF/LC meal when calculated 
from the LC-MS/MS data (n = 3). A similar change in triglyceride levels, plus an increase in 
cholesterol ester, is observed when HPLC data is processed through the combined HPLC-
CAD/LC-MS data analysis workflow (Table 1). The combined workflow is advantageous over 
simple quantitation of HPLC-CAD data because it allows for analysis of lipid species that were 
not identified by HPLC-CAD (e.g. ceramides, monoglycerides, and diglycerides), and also allows 
quantitation of free cholesterol and two more cholesterol ester species than what can be detected 
in larval zebrafish samples analyzed with MS/MS detection (Table 1, Supplemental Table S1, and 
Supplemental Table S2).  
 
BODIPY-labeled fatty acids are metabolized by larval zebrafish into different arrays of 
complex lipids depending on fatty acid chain length 
Thin-layer chromatography assays have shown that larval zebrafish fed BODIPY FL-C5, 
-C12, and -C16 in a HF/HC meal incorporate these fluorescent fatty acids into the three major 
classes of complex lipids (phospholipids, triglycerides, and cholesterol esters) in different 
proportions (28). Because HPLC resolves individual lipid species within each class where TLC 
does not, we repeated the experiments of Carten et al. (2011) in order to investigate the 
fluorescent lipid product profile of each of these BODIPY-fatty acids at a higher resolution. 
Larval zebrafish were fed BODIPY FL-fatty acids in a HF/HC meal for two hours, and total 
lipids were extracted after a 16-hour chase period. The products of each BODIPY FL-fatty acid 
were analyzed by HPLC with fluorescence detection, which revealed that carbon chain length of 
fluorescent saturated fatty acids influences their channeling into complex lipids: while BODIPY 
FL-C12 is incorporated into a wide array of nonpolar lipids and phospholipids, BODIPY FL-C16 
and BODIPY FL-C5 are largely incorporated into nonpolar lipids and a smaller amount of 
phospholipid. A single cholesterol ester product (confirmed through the use of standards and an   
&*!
 
Figure 2. Multistep gradient HPLC-CAD facilitates resolution and quantitation of all 
classes of lipids in a single underivatized sample. Several triglyceride species are increased 
in larval zebrafish following a single HF/HC meal while other lipid classes remain unchanged. 
Similar results are obtained when lipid class distribution is quantitated directly from the mass 
spectrometry data set using LipidSearch, and when quantitation of HPLC-CAD analyte peaks 
(identified previously using LC-MS/MS) is performed in Chromeleon (Table 1). The HF/HC 
trace (red) is offset by 12.5 pA (picoamperes). This chromatogram represents results from 3 
independent experiments. 
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Table 1. Lipid class composition of larval zebrafish fed low-fat/low-cholesterol (LF/LC) or 
high-fat/high cholesterol (HF/HC) diets; determined by LC-MS/MS, HPLC-CAD, or the 
combined workflow described in Figure 1. 
 
 Mass Spectrometry HPLC-CAD Combined 
Workflow 
 Percent of total lipida Percent of total lipid Percent of total lipid 
Classb LF/LC HF/HC LF/LC HF/HC LF/LC HF/HC 
Fatty Acid 0.9 ± 0.3 0.8 ± 0.2 1.1 ± 0.8 0.6 ± 0.2 0.2 ± 0.1 0.2 ± 0.1 












Triglyceride 0.5 ± 0.1 4.8 ± 1.1 6.1 ± 3.6 12.6 ± 3.5 0.7 ± 0.3 7.4 ± 1.9 
Diglyceride 0.1 ± 0.1 0.1 ± 0.0 -c -c 0.8 ± 0.4 0.6 ± 0.2 
Monoglyceride 0.2 ± 0.1 0.1 ± 0.1 -c -c 13.3 ± 
10.5 
4.9 ± 2.8 
LPL 0.6 ± 0.2 0.6 ± 0.2  1.4 ± 1.1 0.4 ± 0.3 1.2 ± 0.7 0.8 ± 0.3 
Ceramide 0.7 ± 0.2 0.6 ± 0.2 -c -c 0.7 ± 0.3 0.6 ± 0.2 
CE 0.0 ± 0.0 0.0 ± 0.0 3.1 ± 1.2 5.4 ± 1.4 1.7 ± 0.5 2.8 ± 0.8 
Cholesterol -c -c 26.3 ± 
6.3 




Other 2.7 ± 1.0 2.6 ± 0.7 -c -c 11.6 ± 
0.9 
1.4 ± 0.4 
aLipids are quantitated by class as a percentage of the total signal ± standard deviation (n = 3). 
bLPL: lysophospholipid, CE: cholesterol ester 
cLipid class could not be identified and/or quantitated by this method. 
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ACAT inhibitor, data not shown) of each BODIPY FL-fatty acid was observed. No oxidation 
intermediates of BODIPY FL-fatty acids were found (Figure 3, Table 2). 
Though resolution and quantitation of individual complex lipid products of BODIPY FL-FAs was 
achieved by HPLC-fluorescence, it was not practical to use standards to identify each putative 
fluorescent phospholipid and triglyceride peak due to the number of possibilities. MS detection 
identified 31 unlabeled fatty acids in larval zebrafish that could combine with BODIPY FL-FAs 
to form fluorescent complex lipids with the observed retention times, which gives a total of 273 
possible phospholipid products and 496 possible triglyceride products of each BODIPY FL-fatty 
acid (assuming none are double-labeled, which is unlikely due to the low ratio of labeled to 
unlabeled dietary fatty acids in these experiments).  
Based on retention times of purchased standards and non-fluorescent peaks identified by 
LC-MS/MS, we hypothesized that fluorescent peaks eluting between 15 and 45 minutes on the 
HPLC-Fluorescence chromatograms in Figure 3 were phospholipids and fluorescent peaks eluting 
between 45 and 80 minutes were nonpolar lipids (e.g., triglycerides and sterol esters). To test this 
hypothesis, total lipid extracts from larval zebrafish fed BODIPY FL-fatty acids in a HF/HC meal 
were subjected to acetone precipitation to separate polar and nonpolar fractions, each of which 
was analyzed by HPLC with fluorescent detection (Supplemental Figure S1).  These data 
confirmed that the predicted class of each peak was as expected. For more precise identification 
of specific fluorescent complex lipids, the products of each BODIPY FL-fatty acid were also 
analyzed by LC-MS/MS as described above, and the unique isotopic signature of boron was used 
to identify putative BODIPY-lipids. Five BODIPY FL-C12 phospholipids, two BODIPY FL-C5 
phospholipids, a BODIPY FL-C16 triglyceride, and the cholesterol esters of BODIPY-FL C5 and 
BODIPY FL-C12 were identified by this method (Supplemental Table S4). Fluorescent fatty 
acids are especially useful metabolic labeling reagents in the larval zebrafish model because 
biochemical and live imaging assays may be performed in parallel. The fluorescent lipid feeding 
procedures used in this study are well established as methods to investigate dietary lipid transport   
'-!
Table 2.  Distribution of fluorescent products of BODIPY-FL fatty acids among the major 





Triglycerides Total polar:total 
nonpolar lipids 
BODIPY FL-C5 n/aa 7.5 ± 1.3 9.6 ± 0.6 82.9 ± 1.9 0.08 
BODIPY FL-
C12 
1.5 ± 0.7 39.5 ± 1.4 11.0 ± 1.3 48.0 ± 2.0 0.67 
BODIPY FL-
C16 
5.5 ± 1.6 5.6 ± 0.5 3.0 ± 0.5 85.9 ± 2.0 0.06 
aFree BODIPY FL-C5 could not be quantitated in this assay as it runs in the solvent front. 
Fluorescent products of BODIPY FL-fatty acids fed to larval zebrafish in a HF/HC meal are 
quantitated by class as percentage of total fluorescence ± standard deviation (n = 3 for BODIPY 
FL-C5, n = 6 for BODIPY FL-C12 and -C16).  
Figure 3. The chain length of BODIPY FL-labeled saturated FAs affects their 
incorporation into complex lipids. HPLC-fluorescence analysis resolves products of 
BODIPY FL-C5, -C12, and -C16 synthesized by larval zebrafish that have been given these 
fluorescent FAs in a HF/HC meal. Results are representative of >10 independent HPLC-
fluorescence analyses of total lipid extracts taken from 6 dpf larval zebrafish sampled 16–
20h postfeeding. 
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Supplemental Figure S1  
'%!
Supplemental Figure S1, continued  
Supplemental Figure S1. Fluorescent products of BODIPY FL-fatty acids were 
identified as polar or nonpolar lipids by acetone precipitation followed by HPLC.  
A) Products of BODIPY FL-C5 running at 15-22.5 minutes are enriched in the polar fraction. 
Products running between 45 and 65 min are enriched in the nonpolar fraction. B) Products of 
BODIPY FL-C12 running before 35 minutes are enriched in the polar fraction, and products 
running after 35 min are enriched in the nonpolar fraction. C) Two polar products of BODIPY 
FL-C16 elute between 30 and 40 min. All other products are nonpolar. Results on each 
chromatogram are representative of 3 samples per group. 
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and deposition in tissues, cells, and subcellular structures in the larval zebrafish as well as other 
models (5, 88, 104). At 4-8 hours from the start of feeding BODIPY FL-C5 in a HF/HC meal, 
fluorescence is seen by live confocal microscopy in a variety of subcellular structures and 
membranes in the larval zebrafish liver, pancreas, and intestinal enterocytes, while BODIPY FL-
C16-derived fluorescence in these organs is concentrated in lipid droplets (28). Based on this 
previously published imaging data, we expected to detect a larger amount of phospholipid 
products of BODIPY FL-C5 when compared with BODIPY FL-C16. This hypothesis was 
supported by HPLC-Fluorescence lipid profiles, in which the products of BODIPY FL-C5 in 
samples taken 8 hours post-feeding are 6.6 ± 1.3% phospholipid (n = 13) and products of 
BODIPY FL-C16 in samples taken 6-10 hours post-feeding are 2.1 ± 0.5% phospholipid (n = 4, p 
= 0.000012; Student’s T-test).  
As all variants of the BODIPY fluorophore are large compared with the labeled fatty 
acids, we hypothesized that the metabolism of BODIPY-fatty acids would not exactly replicate 
that of their unlabeled counterparts but would resemble the metabolism of larger fatty acids. 
Specifically, as the BODIPY FL fluorophore is approximately the length of a 4-carbon chain, we 
tested the hypothesis that BODIPY FL-C12 and 3H-palmitate would yield similar product 
profiles.  BODIPY FL-C12 and 3H-palmitate were fed to larval zebrafish in equimolar amounts in 
a HF/HC meal, and products were analyzed 18 hours post-feeding by HPLC.  Following 
fluorescent detection, HPLC eluent was collected in one-minute fractions which were assayed for 
radioactivity so that the metabolism of both radioactive and fluorescently labeled fatty acids 
could be characterized simultaneously. The complex lipid product profiles of BODIPY FL-C12 
and 3H-palmitate, while not identical, contain similarly high ratios of labeled phospholipid to 
labeled nonpolar lipid when compared with the products of BODIPY FL-C5 and BODIPY FL-
C16 (Tables 2,3). Full product profiles of BODIPY FL-C12 and 3H-palmitate present in larval 


























Supplemental Figure S2. BODIPY FL-C12 and 3H-C16 form similar product arrays 
when fed to larval zebrafish. Larval zebrafish were fed equimolar amounts of BODIPY FL-
C12 and palmitic acid in a HF/HC meal, and then sampled for lipid extraction 18 hours post-
feeding (n = 4). HPLC analysis of complex lipid products is summarized above. Blue bars 
represent the percentage of total radioactive signal present in each one-minute fraction 
(products of 3H-C16), and red bars represent the percentage of total area under the curve of 
the fluorescent chromatogram present in each one-minute segment (products of BODIPY FL-
C12). 8 min = free BODIPY FL-C12, 19 min = free 3H-C16, 1-7 min and 20-40 min = 
fluorescent polar lipids, 20-50 min = radioactive polar lipids, 41-61 min and 63-80 min = 
fluorescent triglycerides, 51-77 min and 79-80 min = radioactive triglycerides, 62 min = 
Cholesterol BODIPY FL-C12, 78 min = Cholesterol 3H-C16. Radioactive lipids eluting before 
19 minutes could not be identified as lysophospholipids or fatty acid oxidation intermediates 
within the scope of this study, and were not included in the data analysis. 
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Table 3.  Distribution of labeled products of BODIPY FL-C12 and 3H-C16 fatty acids 
among the major lipid classes, 18 hours post-feedinga.  










22.5 ± 6.2b 43.4 ± 7.4 9.9 ± 0.4 24.2 ± 1.3 1.27 
3H-C16 4.3 ± 0.7 76.8 ± 4.0 2.4 ± 0.6 16.5 ± 2.9 4.06 
aLarvae were fed and incubated post-feeding at room temperature. For all other experiments, 
feeding was conducted at 30oC. 
bProducts of labeled fatty acids fed to larval zebrafish in a HF/HC meal are quantitated by class as 
percentage of total signal ± standard deviation (n = 4). 
 
Fluorescent lipid analogs of similar chain lengths and different fluorescent tags are 
metabolized by larval zebrafish into different arrays of complex lipid products 
As BODIPY FL-C12 is especially physiologically relevant due to its similarity to 
palmitate and forms a wider array of polar and nonpolar products than the other two BODIPY 
FL-fatty acids examined, we focused on this chain length for the remaining experiments, which 
addressed the effects of dietary context and variants of the BODIPY fluorophore on the 
metabolism of fluorescent fatty acids. In addition to BODIPY FL, lipids labeled with many other 
variants of BODIPY are commonly used in live fluorescent microscopy. As BODIPY-labeled 
fatty acids are metabolizable, the fluorescent signal in live imaging experiments is derived not 
only from the BODIPY-fatty acid but also from its metabolic products. To better understand how 
differences in BODIPY fluorophores impact the metabolism of labeled fatty acids and possibly 
the subcellular localization of their products, we set out to explore the effect of varying 
fluorophore chemistry with constant fatty acid chain length. 
BODIPY(558/568)-C12 fluoresces red and is therefore especially useful in fluorescent 
microscopy experiments involving cells or animals expressing GFP. This red fluorescent tag, at 
272 g/mol, is substantially larger than BODIPY FL (218 g/mol) and carries an additional 5-
member thienyl ring structure (Figure 4 inset). Previous work comparing the metabolism of the  
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Figure 4. BODIPY FL-C12 and BODIPY(558/568)-C12 are processed similarly to each 
other when fed to larval zebrafish in a HF/HC meal. A) When BODIPY FL-C12 and 
BODIPY(558/568)-C12 are fed simultaneously in a HF/HC meal, they label the same 
subcellular structures in the larval zebrafish liver 8 hours post-feeding. Scale bar: 25 µm. B) 
Similar arrays of phospholipid, triglyceride, and cholesterol ester products of BODIPY FL-
C12 and BODIPY(558/568)-C12 are observed 8 hours post-feeding, though the products form 
in different proportions to each other. Results are representative of 6 samples per group. 
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red and green BODIPY-C12 variants by mouse primary hepatocytes showed by qualitative TLC 
assays that both of these fluorescent fatty acids are incorporated into both nonpolar complex 
lipids and phospholipids (91). Because the BODIPY tag accounts for over half of the molecular 
weight and over 25% of the length of the BODIPY-C12 molecule, we hypothesized that structural 
differences between BODIPY variants would correlate with differences in the metabolism of 
BODIPY-lipids that could be quantitated by HPLC-fluorescence.  
To test this hypothesis, a mixture of BODIPY FL-C12 and BODIPY(558/568)-C12 in a 
HF/HC meal was fed to larval zebrafish, which were imaged by live confocal microscopy 8 hours 
post-feeding. Red and green fluorescence, derived from the products of both BODIPY-C12 
variants, appear in the same subcellular structures in the larval zebrafish liver (Figure 4A).  
Additionally, similar arrays of complex lipid products are observed when each of these 
fluorescent fatty acids is fed individually (also in a HF/HC meal) and HPLC-Fluorescence is 
performed on samples taken 8 hours post-feeding (Figure 4B). However, the relative amounts of  
each BODIPY-C12 product vary depending on the type of BODIPY tag: BODIPY FL-C12 is 
more readily metabolized into complex lipid products than BODIPY(558/568)-C12, and is  
incorporated mostly into polar lipids, while BODIPY(558/568)-C12 is incorporated mostly into 
triglycerides (Table 4). 
 
Table 4. BODIPY FL-C12 and BODIPY(558/568)-C12 are incorporated into similar 
products, but in different proportions.  
 Fatty acid Polar lipids Cholesterol ester Triglycerides 
BODIPY FL-C12 2.3 ± 0.1a 59.7 ± 0.8 14.2 ± 1.5 23.7 ± 0.8 
BODIPY(558/568)-C12 6.6 ± 0.2 23.8 ± 1.0 11.9 ± 1.4 60.0 ± 0.8 
aFluorescent products of BODIPY FL-fatty acids fed to larval zebrafish in a HF/HC meal and 
analyzed 8h post-feeding are quantitated by class as percentage of total fluorescence ± standard 




To further examine the effect of BODIPY variant on BODIPY-fatty acid partitioning in 
the larval zebrafish, we carried out similar feeding and HPLC-Fluorescence experiments using 
the fluorescent fatty acid TopFluor®-C11. TopFluor is a green variant of BODIPY that carries 
two additional methyl groups and is bonded to its lipid conjugate at carbon 1 of its central ring, 
forming a T-shaped molecule in contrast with the more linear BODIPY FL-fatty acids (Figure 5 
inset). We hypothesized that though the fluorophores are chemically similar, the position at which 
the labeled lipid is attached may result in variations in metabolism. When fed to larval zebrafish 
in a HF/HC meal, TopFluor-C11 is processed into an array of products similar in class to the 
products of BODIPY FL-C12, though the specific fluorescent HPLC peaks that appear are 
different (compare Figures 3 and 5).   
 
Fluorescent lipid analogs of similar chain lengths are metabolized by larval zebrafish into 
different arrays of complex lipid products when dietary lipid content is varied 
We then set out to explore the effect of dietary lipid content on fluorescent lipid 
metabolism, again using BODIPY FL-C12, the most widely metabolized BODIPY FL-fatty acid. 
LF/LC and low-fat/high-cholesterol (LF/HC) diets were investigated as BODIPY-lipid carriers. 
BODIPY FL-C12 fed in a LF/LC or LF/HC meal is used to make an array of complex lipid 
products similar to those synthesized when this fluorescent fatty acid is fed in a high-
fat/cholesterol meal, but in different proportions (Figure 6 [upper trace], Table 5). 
(Chromatograms in Figure 6 show the fluorescent lipid products of BODIPY FL-C12 and 
BODIPY (558/568)-C12 delivered to larval zebrafish in LF/LC meals. Results are similar for 
these fluorescent fatty acids fed in LF/HC meals [chromatograms not shown; quantitative data is 
summarized in Table 5].) Specifically, similar amounts of fluorescent phospholipid are 
synthesized when BODIPY FL-C12 is fed in all three diets, but with the HF/HC diet less 
fluorescent cholesterol ester (HF/HC-fed larvae: CE = 11.0 ± 1.3 % of total) and more fluorescent   
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Figure 5. HPLC-Fluorescence product profile of the BODIPY-lipid TopFluor-C11. 
Larval zebrafish synthesize a similar array of polar and nonpolar lipids from BODIPY FL-
C12 (Figures 3 and 6) and TopFluor-C11 when these fatty acid analogs are delivered in a 
HF/HC meal. Products of TopFluor-C11 20 hours post-feeding are 1.6 ± 0.1% free TopFluor-
C11, 22.1 ± 1.7% polar lipids, and 76.0 ± 1.5% nonpolar lipids (n = 3). Unlike BODIPY FL-
C12, some oxidation intermediates of TopFluor-C11 (eluting before 5 min) may be present. 
No cholesterol ester of TopFluor-C11 was identified. 
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Figure 6. The array of complex lipid products formed when BODIPY-C12 is fed to 
larval zebrafish in a LF/LC diet varies depending on the type of BODIPY label. BODIPY 
FL-C12 fed in a LF/LC meal is used to make an array of polar and nonpolar lipid products 
similar to those synthesized when this fluorescent fatty acid is fed in a HF/HC meal (Figure 
4), but in different proportions. In contrast, BODIPY(558/568)-C12 is no longer incorporated 
into a detectable amount of phospholipid when delivered in a LF/LC diet. Results are 
representative of 5 samples per group. 
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Table 5. BODIPY-lipids with similar fatty acid chain lengths are metabolized differently 
depending on the BODIPY variant, BODIPY-lipid class, and cholesterol content of the diet. 
 Products of BODIPY-Lipid Fed in LF/LC Diet Products of BODIPY-Lipid Fed in LF/HC Diet 
BODIPY-Lipid %FAa %PL %TG %CE %FA %PL %TG %CE 
BODIPY FL-C12 no signal 40.1 ± 5.2* 16.9 ± 1.7 42.9 ± 3.6* no signal 29.3 ± 0.2* 19.5 ± 2.2 51.2 ± 2.0* 
BODIPY(558/568)
-C12 
15.8 ± 3.0 no signal 52.5 ± 1.2 31.7 ± 3.0 45.9 ± 
17.2 
no signal 34.1 ± 11.8 20.0 ± 8.9 
Cholesterol 
BODIPY FL-C12 




no signalb no signalb no signalb no signalb no signal no signal 58.9 ± 3.8 41.1 ± 3.8 
aFluorescent products of BODIPY-lipids fed to larval zebrafish in a HF/HC meal are quantitated 
by class as percentage of total fluorescence ± standard deviation. 
bn = 2. For all other groups, n = 3.  
*p<0.05 when LF/LC and LF/HC groups are compared by Student’s t-test. 
 
triglyceride is made when compared with the LF/LC (CE = 42.9  ± 3.6 % of total) and LF/HC 
meals (CE = 51.2  ± 2.0 % of total) (Tables 4 and 5). We hypothesize that the larger amount of 
fatty acid in the HF/HC diet generally increases triglyceride synthesis and therefore causes more 
fluorescent fatty acid to be channeled into triglycerides when compared with the LF/LC and 
LF/HC diets. Addition of cholesterol to a low-fat meal also correlates with increased cholesterol 
ester synthesis from BODIPY FL-C12, at the expense of incorporation into phospholipid (Table 
5, p<0.05).  
We then sought to determine whether high dietary cholesterol had a similar effect on the 
metabolism of the red fluorescent fatty acid BODIPY(558/568)-C12. BODIPY(558/568)-C12 
contributes fluorescence to all four lipid classes that were measured when delivered in a HF/HC 
meal (Table 4), but is no longer metabolized into a detectable amount of phospholipid when 
delivered in a LF/LC or LF/HC meal (Table 5). No significant differences were observed between 
the fluorescent product profiles of BODIPY(558/568)-C12 delivered in a LF/LC or LF/HC diet 
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(Table 5). In general, BODIPY(558/568)-C12 appears to be metabolized into complex lipid 
products to a lesser extent than BODIPY FL-C12. 
 
Metabolism of BODIPY-cholesterol esters by larval zebrafish is responsive to the 
cholesterol content of the diet and the BODIPY variant 
Stoletov et al (2009) established the larval zebrafish as a model for hypercholesterolemia 
in which they observed fluorescent punctae in blood vessels of larval zebrafish fed a red 
fluorescent cholesterol ester analog (cholesterol BODIPY(576/589)-C11) for several days in a 
high-cholesterol diet (83). The chemical composition of BODIPY-lipids labeling these punctae, 
however, was not known. As the fluorescent label of cholesterol BODIPY(576/589)-C11 is 
located on the acyl chain, we hypothesized that the fluorescent acyl chain would be cleaved from 
the cholesterol molecule in the intestine by luminal lipases, and that it would subsequently be 
metabolized like a BODIPY-fatty acid. To test this hypothesis and gain a better understanding of 
the larval zebrafish as a model of nascent hypercholesterolemia, we repeated the experiments of 
Stoletov et al with HPLC-CAD/Fluorescence analysis, with the addition of larval zebrafish fed 
cholesterol BODIPY FL-C12 for comparison. Each BODIPY-cholesterol ester was added to 
LF/LC or LF/HC food, and total lipids were extracted from larval zebrafish after three days of 
feeding. No fluorescent products of BODIPY(576/589)-C11 were recovered from larval zebrafish 
fed this fluorescent lipid in the LF/LC diet, suggesting that cholesterol BODIPY(576/589)-C11 is 
excreted without being digested or absorbed (Table 5, Supplemental Figure S3A). A separate 
series of HPLC-Fluorescence experiments confirmed that cholesterol BODIPY(576/589)-C11 
was present in the food given to this experimental group, and in larvae that still had visible food 
particles in their intestines (data not shown). When cholesterol BODIPY(576/589)-C11 was 
delivered in a LF/HC diet, however, fluorescent triglycerides and cholesterol BODIPY(576/589)-
C11 were detected. In contrast, fluorescence derived from cholesterol BODIPY FL-C12 delivered 
in a LF/LC or LF/HC meal appeared in an array of products similar to those produced by feeding  
(&!
Figure 7. When the fluorescent CE cholesterol BODIPY FL-C12 is fed to larval 
zebrafish in a LF/HC diet, fluorescent phospholipid, triglyceride, and cholesterol ester 
products are observed. Cholesterol BODIPY(576/589)-C11 yields fluorescent triglyceride 
(Supplemental Figure S3B) and cholesterol ester products when delivered in a LF/HC diet. 
Results are representative of 4 samples per group. 
('!
Supplemental Figure S3. Dietary cholesterol is required for metabolism of red 
BODIPY-labeled CE. A) When cholesterol BODIPY FL-C12 is fed to larval zebrafish in a 
LF/LC diet, fluorescent cholesterol ester, phospholipid, and triglyceride products are 
observed. Cholesterol BODIPY(576/589)-C11 yields no fluorescent products when fed in a 
LF/LC diet. Results are representative of 4 samples per group. B) Cholesterol 
BODIPY(576/589)-C11 yields a cholesterol ester and three triglyceride products when fed 
in a LF/HC diet. This sample from the experiment depicted in Figure 7 was overloaded (for 
the cholesterol ester) in order to allow visualization and quantitation of the fluorescent 
triglycerides. 
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the fatty acid BODIPY FL-C12 (Figure 7, Supplemental Figure S3, Table 5). These results 
suggest that fluorescent lipid punctae observed in larval zebrafish blood vessels may be labeled 
by a mixture of fluorescent triglycerides and cholesterol esters, and that cholesterol BODIPY FL-
C12 is more readily metabolized by larval zebrafish than its red counterpart cholesterol 
BODIPY(576/589)-C11. 
 
Incorporation of dietary BODIPY-labeled fatty acid analogs into cholesterol esters is 
responsive to the availability of dietary cholesterol for uptake by enterocytes 
To further investigate the role of cholesterol in regulating the metabolism of dietary fatty 
acids, we sought to understand the effect of the metabolic availability of dietary cholesterol on the 
partitioning of dietary fluorescent fatty acids among complex lipid classes. Using two  
pharmaceutical inhibitors of cholesterol absorption and metabolism, we set out to explore the 
degree to which we could track cholesterol metabolism and its influence on dietary fatty acid 
partitioning by monitoring fluorescent cholesterol ester synthesis. Ezetimibe is an inhibitor of 
dietary cholesterol absorption by enterocytes that acts by interfering with the npc1l1 cholesterol 
uptake pathway. It has been shown to decrease absorption of dietary radioactive cholesterol or 
fluorescent cholesterol analogs by 70-80% in humans, other mammals, and larval zebrafish (41, 
46, 48, 105). 4-hydroxycinnamic acid (L-phenylalanine methyl ester) amide (CAY10486, 
Cayman Chemical) is an ACAT inhibitor that has been shown to reduce cholesterol ester 
synthesis by 70% in mammalian cell culture and by 40% in 3 dpf larval zebrafish (23, 106). We 
hypothesized that because a high-cholesterol diet increased cholesterol ester synthesis from 
dietary fluorescent fatty acids, limiting cholesterol absorption would have the opposite effect. 
Treatment of larval zebrafish with ezetimibe or an ACAT inhibitor before, during, and after a 
HF/HC meal containing BODIPY-labeled fatty acids resulted in a statistically significant 
decrease in fluorescent cholesterol ester synthesis (Table 6). The respective decreases in 
cholesterol ester synthesis resulting from treatment with ezetimibe and the ACAT inhibitor were  
	 56	
 
Table 6. Cholesterol ester synthesis from dietary fatty acids is decreased by blocking dietary 
cholesterol absorption.  
 5 µM Ezetimibe 100 µM ACAT Inhibitor 
BODIPY-fatty acid Cholesterol ester 
(treated:control) a 
p-value Cholesterol ester 
(treated:control) a 
p-value 
BODIPY FL-C5 0.73 ± 0.08 0.02* 0.64 ± 0.07 0.005* 
BODIPY FL-C12 0.52 ± 0.16 0.004** 0.44 ± 0.05 0.0007* 
BODIPY(558/568)-C12 0.35 ± 0.02 0.002* 0.61 ± 0.12 0.018* 
BODIPY FL-C16 0.25 ± 0.10 0.0003** 0.19 ± 0.03 0.00005* 
aFold changes are given as the treated:control group ratio of the average CE peak area per larval 
equivalent in samples taken 18 hours post-feeding, ± standard deviation. All sample groups pass 
Levene’s test for equal variance.  
*Student’s t-test, unpaired, equal variance, n = 3.  
**Nested ANOVA, df = 11 (2 experiments; 2-3 technical replicates per group per experiment). 
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within one standard deviation of each other in experiments with both BODIPY FL-C12 and 
BODIPY FL-C16. Neither ezetimibe nor the ACAT inhibitor altered the total cholesterol content 
of larval zebrafish in a 48-hour drug treatment period with a single HF/HC meal (Supplemental 
Figure S4B). Changes in cholesterol ester synthesis from fluorescent dietary fatty acids observed 
in these experiments were determined by dissection to take place in the intestine (Figure 8 and 
Supplemental Figure S5), suggesting that cholesterol ester synthesis from newly absorbed dietary 
fatty acids depends primarily on availability of newly absorbed or synthesized cholesterol.  
Discussion 
 
Mass spectrometric detection and identification of lipids is an increasingly prevalent 
approach to lipidomics that provides a wealth of highly detailed information per experimental 
sample. However, when compared with other biochemical techniques, MS is expensive and time-
consuming, which can unnecessarily limit the scope of lipidomic studies. Our combined HPLC-
CAD/LC-MS workflow leverages the strengths of both MS and CAD lipidomics by enhancing 
the depth of information that may be obtained from HPLC-CAD experiments with a lower cost 
per sample.  
The first published metabolic assays using BODIPY FL-C12 showed that in mammalian 
cell culture this fluorescent fatty acid is incorporated into diglycerides, triglycerides, and three 
classes of phospholipids identified by HPLC-Fluorescence.  However, this analysis was limited in 
that BODIPY-labeled phospholipids clustered by class and polar and nonpolar fluorescent lipids 
had to be analyzed separately(87). Our method provides both greater resolution of individual 
fluorescent complex lipids, and a way to analyze all classes of complex lipids from a single 
sample. Furthermore, we have built upon earlier work (28) to expand the metabolic labeling 
toolbox for the larval zebrafish and other model systems by using this method to characterize the 
complex lipid product profiles of a wider range of fluorescent lipids delivered in a variety of diets 
(Table 7).   
(+!
Supplemental Figure S4. Total cholesterol content of larval zebrafish is unchanged by 
ezetimibe, an ACAT inhibitor, and cholesterol content of the diet. A) There are no 
statistcally significant differences in cholesterol peak area per larva in larval zebrafish that 
have been given a single HF/HC meal, or fed LF/LC or LF/HC food for five days and fasted 
24 hours before samples were taken (LF/LC-fed larvae: n = 4, LF/HC-fed larvae: n = 3, 
HF/HC-fed larvae: n = 2). B) There are no statistically significant differences in cholesterol 
HPLC peak area per larva resulting from treatment of larvae with ACAT inhibitor or 
ezetimibe prior to feeding BODIPY FL-C12 in an HF/HC meal and subsequent HPLC 
analysis of samples taken 18 hours post-feeding (n = 3; quantitation performed on HPLC 
CAD traces from experiments summarized in Table 5; Student’s T-tests). Error bars 
represent 1 SD. 
(,!
Figure 8. Ezetimibe reduces cholesterol ester synthesis from dietary fatty acids in the 
intestine. Larval zebrafish (6 dpf) were treated with ezetimibe (or 0.1% ethanol vehicle) and 
then fed BODIPY FL-C12 in the HF/HC diet. Intestines were dissected from 35 larvae per 
group 20 hours post-feeding and pooled for lipid extraction. The cholesterol BODIPY FL-C12 
peak is present in the HPLC-Fluorescence trace from intestines of larvae in the vehicle control 
group (upper chromatogram), and absent in the trace from intestines of ezetimibe-treated 
larvae (lower chromatogram). Results are representative of two samples per group.  
)-!
Supplemental Figure S5. Changes in cholesterol ester synthesis associated with ezetimibe 
treatment occur in the intestine.  Full chromatograms from the experiment in Figure 8. 
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Table 7. Summary of BODIPY lipids, diets and product classes synthesized by larval 
zebrafish. Each fluorescent HPLC peak is counted as a single product of its corresponding 
BODIPY-lipid. 






BODIPY FL-C5 Green HF/HC 5 26 1 
BODIPY FL-C12 Green HF/HC 10 24 1 
BODIPY FL-C12 Green LF/LC 15 18 1 
BODIPY FL-C12 Green LF/HC 15 18 1 
BODIPY(558/568)-C12 Red HF/HC 7 11 1 
BODIPY(558/568)-C12 Red LF/LC 0 3 1 
BODIPY(558/568)-C12 Red LF/HC 0 3 1 
TopFluor-C11 Green HF/HC 11 22 0 
BODIPY FL-C16 Green HF/HC 5 11 1 
Cholesterol BODIPY FL-C12 Green LF/LC 3 11 1 
Cholesterol BODIPY FL-C12 Green LF/HC 3 11 1 
Cholesterol BODIPY(576/589)-
C11 
Red LF/LC 0 0 0 
Cholesterol BODIPY(576/589)-
C11 




Our results demonstrate that although all BODIPY-lipids tested were metabolized into 
multiple fluorescent complex lipid products when fed to larval zebrafish, the resulting product 
profiles varied with chain length of the labeled fatty acid, BODIPY-lipid class, BODIPY 
fluorophore variant, and nutritional context (Table 7). Awareness of this variation in distribution 
of fluorescent signal among lipid classes is not only essential when selecting BODIPY-lipids for 
metabolic labeling experiments, but is also crucial to understanding and interpreting live imaging 
experiments using BODIPY-lipids. For example, emission wavelength is a reasonable primary  
criterion when choosing a BODIPY tag for imaging experiments because it is often necessary to 
choose a fluorescent lipid color different from that of the fluorescent proteins expressed in 
transgenic animal models or cell lines. 
However, when interpreting results obtained with different BODIPY variants or 
fluorescent fatty acids of different chain lengths it is important to consider that differences in the 
distribution of fluorescent signal into lipid classes may have an effect on the distribution of 
fluorescent signal among subcellular membranes and structures. Additionally, feeding larval 
zebrafish lipids labeled with the red BODIPY variants generally results in a larger percentage of 
unincorporated substrate and smaller range of complex lipid products when compared with green 
BODIPY-lipids. We hypothesize that the larger red BODIPY fluorophore slows uptake of 
fluorescent fatty acids into enterocytes and/or subsequent enzymatic interactions required for 
complex lipid synthesis; however, it is also possible that red BODIPY-lipids are more susceptible 
to lipolysis and that the larger amount of substrate observed is due to faster turnover. Even in 
experiments where labeling of cellular structures does not vary with the type of BODIPY 
fluorophore under one set of conditions (e.g., labeling of the same subcellular structures by red 
and green BODIPY-C12 in Figure 4A despite their different metabolic product profiles in Figure 
4B), it cannot be assumed that this will hold true when conditions are varied or that any changes 
in labeling that occur under different experimental conditions will involve the same mechanisms 
for different BODIPY-lipids. 
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Of the BODIPY-lipids examined in this study, the partitioning of BODIPY FL-C12 into 
complex lipid classes most closely resembles the metabolism of palmitic acid, the most abundant 
fatty acid in larval zebrafish.  Radioactive palmitic acid fed to larval zebrafish is incorporated into 
complex lipids more quickly than BODIPY FL-fatty acids, but the distribution of signal among 
polar and nonpolar complex lipids is more similar to that observed with BODIPY FL-C12 than 
any other fluorescent fatty acid examined (Tables 2 and 3). Furthermore, a similar array of 
individual complex lipid products are labeled by radioactive palmitate and BODIPY FL-C12, 
though HPLC retention times are consistently shifted earlier by the BODIPY tag (Supplemental 
Figure S2). Our results are consistent with a model in which the BODIPY fluorophore delays 
uptake of labeled lipids by cells, but does not alter the distribution of labeled lipids among 
complex lipid products. 
In contrast to the product profile of BODIPY FL-C12, incorporation of fluorescent lipids 
into phospholipid occurs at a lower rate with BODIPY FL-fatty acids much larger or smaller than 
the saturated fatty acids most commonly found in zebrafish phospholipids, 16:0, 18:0, and 18:1 
(Supplemental Table S1) (23). BODIPY FL-C5 and –C16, which correspond approximately in 
total length to nine- and 20-carbon unlabeled fatty acids, are incorporated into less phospholipid 
than BODIPY FL-C12 or 3H-palmitate. Incorporation of fluorescent fatty acids into phospholipid 
also appears to be more sensitive to the effects of the larger red fluorophore than incorporation 
into nonpolar lipids. Multiple mechanisms could account for these metabolic differences, 
including effects on digestion, uptake by enterocytes, esterification, and turnover of labeled 
lipids. One possibility is that BODIPY-fatty acids impede diglycerides from interacting with the 
phospholipid synthesis pathway enzymes, but do not hinder their ability to bind or be esterified 
by DGAT. As the fatty acid composition of phospholipids is regulated to maintain membrane 
composition, we expect substrate fatty acid specificity to be more stringent for enzymes involved 
in phospholipid synthesis and remodeling than for those involved in synthesis of the nonpolar 
storage lipid classes TAG and CE. Additionally, the relative contributions of de novo synthesis 
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and remodeling of existing phospholipids to the incorporation of fluorescent fatty acids into 
phospholipid in the larval zebrafish intestine remain to be determined. Future work addressing 
these issues will clarify the physiological mechanisms underlying differential processing of the 
various BODIPY-lipids. 
Despite early evidence for the synthesis of complex lipids from BODIPY FL-fatty acids 
in cell culture (87), there have been multiple studies in which metabolism of BODIPY-lipids by 
cultured mammalian cells was assayed by TLC and complex lipid products were not detected (85, 
107, 108). In general, when metabolic products of BODIPY-lipids are observed, they are 
produced by a whole-animal model given BODIPY-lipids in context of a mixed-lipid diet, 
primary cultured cells that would already contain lipid droplets (e.g. hepatocytes), or cell culture 
supplemented with one or more fatty acids (28, 88-91). Our results provide additional evidence 
supporting the hypothesis that metabolism of BODIPY-lipids is observed in some studies and not 
others due to differences in the nutritional context in which BODIPY-lipids are delivered. Larval 
zebrafish preferentially synthesize mixed-acyl triglycerides and phospholipids (Table S1), and the 
delivery of BODIPY-FL fatty acids to larval zebrafish in a mixed-lipid meal has been shown to 
promote their metabolism when compared with delivery in embryo media alone (28).  To build on 
this previous work, we have shown that BODIPY-fatty acids are also metabolized to complex 
lipid products when delivered to larval zebrafish in a standard LF/LC diet, expanding this model 
for use in experiments where the previously validated HF/HC diet consisting of chicken egg yolk 
may be impractical or may confound results by delivering too much unlabeled lipid.  
The BODIPY-lipid, dietary context, and feeding procedure best suited to an experiment 
depends on the application. For example, it is apparent from the results of this study that with 
current HPLC methods the best BODIPY-lipids for monitoring cholesterol ester synthesis in the 
larval zebrafish are BODIPY FL-C12 and -C16 as their fluorescent cholesterol ester product 
peaks are well-isolated from neighboring fluorescent triglycerides, which ensures accurate 
quantitation. The actual effects of both ezetimibe and the ACAT inhibitor on cholesterol ester 
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synthesis from BODIPY FL-C5 and BODIPY(558/568)-C12 may be larger than what was 
observable by the HPLC-Fluorescence method used, as unlike their counterparts derived from 
BODIPY FL-C12 and -C16 the cholesterol BODIPY FL-C5 and cholesterol BODIPY(558/568)-
C12 peaks do not fully resolve from neighboring triglyceride peaks (Figures 3 and 4). This would 
produce a background signal that would increase cholesterol ester peak areas in both control and 
experimental groups, which would lead to an artificially high treated:control peak area ratio 
(Table 6). Further HPLC method development will address this issue. 
Nutritional context was especially important in experiments investigating the metabolism 
of BODIPY-cholesterol esters. Addition of a large amount of cholesterol to a low-fat diet appears 
to promote metabolism of the fluorescent fatty acid group of cholesterol BODIPY(576/589)-C11 
into triglyceride and cholesterol ester products, and there is no evidence of intestinal lipolysis of 
cholesterol BODIPY(576/589)-C11 when it is delivered in a LF/LC diet. (It is not practical to 
deliver BODIPY-cholesterol esters in a high-fat meal as they are not digested well in this context, 
likely due to competition with triglycerides and other unlabeled cholesterol esters for intestinal 
lipases.) We hypothesize that a higher level of cholesterol than that provided by the LF/LC diet is 
needed to promote release of the enzymes necessary for digestion of BODIPY-cholesterol esters, 
and that cholesterol BODIPY FL-C12 with its smaller fluorescent tag is more readily hydrolyzed 
by intestinal lipases than cholesterol BODIPY(576/589)-C11. 
Historically, studies of dietary cholesterol metabolism have tracked esterification using 
radiolabeled cholesterol (92, 93). By using fluorescent fatty acids as metabolic tracers to monitor 
cholesterol esterification by dietary fatty acids, we are able to build upon the current model for 
partitioning of dietary cholesterol in enterocytes. Though a number of genes involved in 
cholesterol channeling have been identified in multiple animal models including the larval 
zebrafish, the stepwise details of how these processes occur and are regulated in enterocytes are 
not fully characterized.  Sorting of dietary sterols begins upon absorption: after entering the 
enterocyte through the NPC1L1 transport pathway, dietary cholesterol is largely retained in the 
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cell while the bulk of absorbed phytosterols are trafficked back to the intestinal lumen through the 
ABCG5/ABCG8 sterol efflux transporter (109). Once dietary cholesterol is transported to the 
endoplasmic reticulum (ER), it may be incorporated into enterocyte membranes, or packaged into 
lipoproteins or lipid droplets with or without being esterified first at the ER membrane by 
ACAT2 (110).  
Though the mechanisms regulating whether or not a newly absorbed dietary cholesterol 
molecule is esterified are still largely unknown, our results suggest that the amount of cholesterol 
ester synthesized from newly absorbed dietary fatty acid is primarily responsive to the amount of 
newly absorbed and metabolically available dietary cholesterol. Cholesterol is abundant in the 
digestive tissues of the 6 dpf larval zebrafish (determined by dissection and HPLC-CAD analysis; 
data not shown), but the cholesterol present before feeding appears to be inaccessible to 
esterification by ACAT, likely due to being located in the plasma membrane (111). There is no 
statistically significant difference in the whole-body cholesterol content of larval zebrafish that 
have been fed HF/HC, LF/LC, or LF/HC meals when experimental samples are taken long 
enough after the withdrawal of food for the contents of the intestinal lumen to clear (Table 1, 
Supplemental Figure S4A). Additionally, neither ezetimibe nor an ACAT inhibitor produces a 
detectable change in total cholesterol within the time frame and treatment parameters of the 
experiments described herein (Supplemental Figure S4B).  This illustrates the importance of 
metabolic labeling in the study of metabolism of a single lipid species, as without the fluorescent 
marker we employed the signal to noise ratio would have been too low to detect changes in 
cholesterol ester synthesis from newly absorbed dietary lipids in enterocytes. Physical segregation 
of ACAT2 from non-ER-located cholesterol pools and/or a lack of transport of cholesterol from 
other cellular structures to the ER may account for this effect; more work must be done to 
elucidate how ACAT2 activity is regulated. The method of tracking cholesterol ester synthesis 
through metabolic labeling with fluorescent fatty acids will be an important complement to 
radioactive labeling methods in further studies of dietary cholesterol processing. 
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In summary, the HPLC-CAD/fluorescence lipidomics methods described allow for high-
throughput analysis of both total lipids and the products of fluorescent metabolic tracers in a 
single sample, using equipment that requires a much lower initial investment and smaller support 
infrastructure when compared with MS methods. The ability to pair this metabolic labeling 
method with live imaging using the same fluorescent lipid reagents is a major advantage of this 
approach. Using this platform we provide the most comprehensive analysis of fluorescent fatty 
acid metabolism to date, new insights into zebrafish models for dyslipidemia, and evidence for 
coupling between dietary cholesterol uptake and esterification.  
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CHAPTER 3 – HPLC LIPID PROFILING OF MICE REVEALS 
EFFECTS OF DIET AND A ROLE FOR INTESTINAL CAVEOLIN 
1 IN REGULATING PLASMA LIPIDS 
 
Contributions 
The paper reproduced below was published in Disease Models and Mechanisms (March 1st, 
2017). For this study I developed sample preparation and analysis methods for determining lipid 
profiles of mouse plasma, liver, and adipose tissue samples by HPLC-CAD. I performed all 
HPLC experiments, quantitated and analyzed the data, performed statistical analyses, wrote the 
parts of the Methods section on HPLC, interpreted the HPLC data with Jessica Otis, and helped to 
edit the manuscript. 
Intestinal epithelial cell Caveolin 1 regulates fatty acid and lipoprotein cholesterol  
plasma levels  
Jessica P. Otis1, Meng-Chieh Shen1, Vanessa Quinlivan1,2, Jennifer L. Anderson1, and Steven A. 
Farber1,2,* 
1 Carnegie Institution for Science, Department of Embryology, Baltimore, MD, 21218, USA 




Caveolae and their structural protein caveolin 1 (CAV1) have roles in cellular lipid processing 
and systemic lipid metabolism. Global deletion of CAV1 in mice results in insulin resistance and 
increases in atherogenic plasma lipids and cholesterol, but protects from diet-induced obesity and 
atherosclerosis. Despite the fundamental role of the intestinal epithelia in the regulation of dietary 
lipid processing and metabolism, the contributions of CAV1 to lipid metabolism in this tissue 
have never been directly investigated. In this study the cellular dynamics of intestinal Cav1 were 
visualized in zebrafish and the metabolic contributions of CAV1 were determined with mice 
lacking CAV1 in intestinal epithelial cells (CAV1IEC-KO). Live imaging of Cav1-GFP and 
fluorescently labeled caveolae cargos shows localization to the basolateral and lateral enterocyte 
PM, suggesting Cav1 mediates transport between enterocytes and the submucosa. CAV1IEC-KO 
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mice are protected from the elevation in circulating fasted low-density lipoprotein (LDL) 
cholesterol associated with a high-fat diet, but have increased postprandial LDL cholesterol, total 
free fatty acids (FA), palmitoleic acid, and palmitic acid. The increase in circulating fatty acids in 
HFD CAV1IEC-KO mice are mirrored by decreased hepatic fatty acids suggesting a non-cell 
autonomous role in IEC CAV1 in promoting hepatic fatty acid storage. In conclusion, CAV1 
regulates circulating LDL cholesterol and several FA species via the basolateral PM of 
enterocytes. These results point to intestinal epithelial cell CAV1 as a potential therapeutic target 
to lower circulating FA and LDL cholesterol, since high levels are associated with development 




Caveolae are flask-shaped pits, 50 to 100 nm in diameter, that form in lipid-rich plasma 
membrane (PM) regions of most vertebrate cells (112). Caveolae vesicle structure is formed by 
oligomers of caveolin proteins; approximately 144 caveolin proteins are present in a single 
caveolae (112). CAV1 is synthesized in the endoplasmic reticulum, transported to the Golgi, and 
upon exit, oligomerizes and associates with lipid-rich membrane regions (112). A threshold level 
of membrane cholesterol is required for caveolae to form (113) and CAV1 can directly bind 
cholesterol (114) and fatty acids (FA) (115). 
Historically recognized for their endocytic function, caveolae also regulate cell-signaling 
pathways, internalization of cell surface receptors and ligands, cell adhesion molecule expression, 
exocytosis, and transcytosis of caveolae cargos (112). Caveolae are also emerging players in lipid 
metabolism. Global CAV1 knockout mice (CAV1KO) mice have severe alterations in circulating 
lipids, including decreased fasting free FA (FFA), increased postprandial FFA (116), increased 
triglycerides (TG) (116, 117), and increased non-high density lipoprotein (HDL) total, free, and 
esterified cholesterol (116-119). CAV1KO mice are insulin resistant (120), but are protected from 
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diet-induced obesity (116) and atherosclerosis (121, 122). The plasma lipid and body mass 
changes in CAV1KO mice have been proposed to result from a variety of mechanisms including 
altered lipid droplet architecture, reduced adipocyte lipid droplet formation (123), and impaired 
adipocyte metabolic flexibility (124), while protection from atherosclerosis is likely due to 
decreased endothelial adhesion molecule expression.  
The cells that line the intestinal epithelia, enterocytes, are highly specialized to 
bidirectionally absorb, transport, and export large quantities of luminal contents and basolateral 
plasma components. However, the mechanisms by which dietary lipids are internalized, 
transported, and externalized by enterocytes, as well as how enterocytes receive adequate lipids 
from adipose stores during fasting, remain incompletely understood. The close association of 
CAV1 with cholesterol, FAs, lipid droplets, and lipid-rich PM regions suggests a role for CAV1 
and caveolae in intestinal lipid metabolism (125). CAV1 is expressed, and caveolae vesicles 
form, in the enterocytes of several species including humans and mice (126-132). Although it is 
known that CAV1 and caveolae are present in enterocytes, several basic aspects of their biology, 
including subcellular localization and metabolic functions, remain unclear.  
Although intestinal cholesterol absorption is not disrupted in mice lacking CAV1 (118), 
isolated intestinal caveolae contain dietary FA (131) and intestinal lipoprotein cholesterol export 
influences plasma cholesterol levels, so intestinal CAV1 may significantly impact cholesterol 
metabolism. Cell culture studies have suggested that CAV1 PM localization may be asymmetric 
in polarized cells such as intestinal enterocytes; however, reports are conflicting. For example, in 
human intestinal cells CAV1 localizes asymmetrically, but the pattern varies by cell type: in 
human T84 colonic adenocarcinoma cells, CAV1 was observed only on lateral membranes (133); 
in human intestinal biopsies, CAV1 was found only on the basolateral surface (127); and in 
Caco2 cells, CAV1 localizes to the apical plasma membrane (126). This imprecise understanding 
of enterocyte CAV1 localization hampers understanding of its functions in health and disease in 
the intestine. 
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  A shortage of studies in live, intact animal models, has limited our understanding of the 
contributions of intestinal CAV1 to enterocyte cell biology and global lipid metabolism. 
Therefore, in this study we harnessed the genetic tractability and optical clarity of the larval 
zebrafish (Danio rerio) to perform live imaging of intestinal Cav1 and caveolae-mediated 
endocytosis for the first time. The zebrafish digestive system is similar to that of the human, 
composed of a liver, gallbladder, and intestine (134), and lipid and lipoprotein metabolism are 
highly conserved (16, 17). Similar to humans and mice, the zebrafish genome contains one cav1 
gene, with two major splice transcripts, and it is expressed in the intestine (135). Zebrafish have 
previously enabled the elucidation of a role for Cav1 in embryonic organogenesis (135, 136) and 
live super resolution imaging of Cav1 in the embryonic tail (137). Additionally, we employed the 
power of the mouse model to generate a tissue-specific Cav1 deletion and determine its 
contribution to global lipid metabolism. Our transgenic zebrafish and knockout mice, combined 
with a innovative approach to assay enterocyte endocytosis in vivo, allows for an unprecedented 
understanding of enterocyte CAV1 cell biology, the effects of enterocyte CAV1 on systemic lipid 
metabolism, and how CAV1 in the intestinal epithelia influence metabolic disease risk through 




Cav1 localizes to the lateral and basolateral PM of zebrafish enterocytes  
We generated Tg(hsp70l:cav1-eGFP) zebrafish which express zebrafish Cav1 tagged 
with GFP and performed live imaging. Cav1 localizes to the basolateral and lateral PM of 
intestinal epithelial cells, but is excluded from the luminal brush border (Fig. 1A). Mean 
fluorescence intensity is 7.5-fold greater on the lateral PM (605.5 relative units) than the brush 
border (80.7 relative units) (one-way ANOVA, p<0.05) (Fig. 1B).   
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Immunofluorescence (IF) confirms that endogenous Cav1 localizes to the lateral and basolateral 
PM, but not the luminal brush border, of enterocytes in larval and adult zebrafish (Fig. 1C,D). As 
Cav1 protein can exist as either a monomer or an oligomer structuring caveolae vesicles, we 
examined EM sections to determine where caveolae vesicles localize. Similar to the localization 
of Cav1, caveolae vesicles are observed on both the basolateral and lateral membranes, but not on 
the brush border (Fig. 1E,F).  
Caveolae-mediated endocytosis occurs only on the basolateral side of enterocytes 
The asymmetric PM localization of zebrafish enterocyte Cav1 suggests that caveolae-
mediated endocytosis occurs between the intestinal epithelia and submucosa, but not the intestinal 
lumen. To test this hypothesis, we developed a technique to visualize endocytosis in live 
Figure 1 (next page). Cav1 and caveolae localize to the basolateral and lateral PM of 
enterocytes. (A) Live imaging of Tg(hsp70l:cav1-eGFP) zebrafish larvae shows 
localization of Cav1-eGFP to the lateral and basolateral plasma membranes (PM) of 
enterocytes, but not the luminal brush border. One enterocyte is outlined, BB: brush 
border, L: lateral membrane, B: basolateral membrane, I: intracellular (6 dpf). (B) Mean 
fluorescence intensity, in relative units, of Cav1-eGFP in subcellular regions of larval 
enterocytes. Data is mean ± s.e.m, n=3: 9 fish per n, 3 areas of each region per fish; 
groups with different letters are significantly different (one-way ANOVA, p<0.05). 
Representative IF images performed with an antibody to CAV1 confirm the polarized PM 
localization of endogenous Cav1 in (C, E) larval (6 dpf) and (D, F) adult zebrafish gut 
epithelia, scale bars represent 5 µm for C and D and 25 µm for E and F. Representative 
EM images of caveolae vesicles observed on the basolateral and lateral PMs of larval (6 




zebrafish larvae based on cell culture studies that use fluorescently labeled endocytic cargos 
(138). We injected fluorescently labeled endocytic cargos that are internalized specifically by 
caveolae (Alexa Fluor-albumin (139-143) and BODIPY-d-LacCer (138, 144)) or clathrin-coated 
vesicles (BODIPY-l-LacCer (138)) to the basolateral or luminal side of enterocytes. Live 
confocal imaging indicated if endocytosis took place from the basolateral/lateral PM (basolateral 
injection) or brush border (luminal injection) in the intestinal epithelia. While BODIPY-l-LacCer, 
the cargo transported specifically by clathrin-coated vesicles, is internalized from both enterocyte 
PM regions, the caveolae-specific cargos Alexa Fluor-albumin and BODIPY-d-LacCer are only 
endocytosed from the basolateral PM (Fig. 2A). The fluorescently labeled caveolae-specific 
cargos localize to similar cellular locations as endogenous Cav1 and Cav1-GFP (lateral and 
basolateral PM), while the clathrin-specific cargo localizes to distinct cellular locations (brush 
border) (Fig. 2A). The mean fluorescence intensity of the lateral PM was 3.45-fold and 11.1-fold 
greater following basolateral injection of Alexa Fluor-albumin and BODIPY-d-LacCer, 
respectively, relative to luminal injection (Student’s t-test, p=0.018 and p=0.003) (Fig. 2B). Two 
lines of zebrafish with mutations in cav1 have recently been published (145); we hypothesized 
that uptake of caveolar cargos would be lost in the enterocytes of the fish. Basolateral albumin 
injections were repeated in the larvae, however uptake of Alexa Fluor-albumin was not decreased 
in cav1PD1094, likely since total cav1 mRNA is not decreased in this line, and cav1PD1104 larvae 
were not healthy enough to survive the experiment in our hands (data not shown; fish generously 
provided by Michel Bagnat). These results suggest that caveolae perform a polarized endocytic 
function in enterocytes, mediating transport between enterocytes and the submucosa, but not the 
intestinal lumen.  
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Figure 2. Fluorescently labeled endocytic cargos enable imaging of caveolar endocytosis in the 
intact zebrafish intestine. (A) Representative images show that the caveolar specific cargos Alexa 
Fluor-albumin and BODIPY-d-LacCer are internalized from the basolateral PM of enterocytes, but 
not the intestinal lumen. In contrast, the cargo transported specifically by clathrin-coated vesicles, 
BODIPY-l-LacCer, is transported into enterocytes from both the basolateral and luminal PMs. BB: 
brush border, L: lateral membrane, B: basolateral membrane, I: intracellular, N: nucleus, arrowhead: 
intracellular puncta. (B) The mean fluorescence intensity of Alexa Fluor-albumin and BODIPY-d-
LacCer on the lateral PM of enterocytes is significantly greater following basolateral injection 
compared to luminal injection. In contrast, the mean fluorescence intensity of BODIPY-l-LacCer on 
the lateral PM of enterocytes is the same following basolateral and luminal injection. Data is 
presented relative to lateral PM mean fluorescence intensity following luminal injection (mean ± 
s.e.m, n=3: 9 fish per n, 3 areas of each region per fish, Student’s t-test, * signifies p<0.05). 
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Generation of intestinal epithelial cell Cav1 KO mice 
While zebrafish are an ideal model to visualize Cav1 and endocytosis, it is extremely 
challenging to perform tissue-specific gene deletion and measurements of plasma metabolites. To 
address this challenge mice lacking CAV1 specifically in intestinal epithelial cells (CAV1IEC-KO) 
were generated by crossing mice with floxed Cav1 (CAV1fl/fl) (146) with Villin-Cre mice (147) 
(Fig. 3A).  PCR of gDNA from whole jejunum (a mixed tissue sample containing non-genetically 
modified smooth muscle and vasculature endothelial cells in addition to intestinal epithelial cells 
lacking CAV1) shows evidence that Cre recombination occurs in the intestine of CAV1IEC-KO 
mice but not in wild type (WT) CAV1fl/fl littermates (Fig. 3B). RT-PCR of jejunum (tissue 
includes epithelial cells as well as submucosa and muscle) demonstrates that Cav1 mRNA is 
decreased ~70% in CAV1IEC-KO mouse relative to CAV1fl/fl WT (Student’s t-test, p=0.01) (Fig. 
Figure 3 (next page). Deletion of Cav1 from mouse intestinal epithelial cells (CAV1IEC-
KO). (A) Schematic representation of deletion of Cav1 in the intestinal epithelium. (B) PCR of 
genomic DNA from whole mouse jejunum shows that Cre recombination of Cav1 has 
occurred in CAV1IEC-KO jejunum but not in CAV1fl/fl WT littermates. (C) Cav1 mRNA is 
decreased 68% in CAV1IEC-KO mouse jejunum as evidenced by RT-PCR (mean, Student’s t-
test, p=0.01, n=10). (D) Cav2 mRNA is decreased 75% in CAV1IEC-KO mouse jejunum as 
evidenced by RT-PCR (mean, Student’s t-test, p=0.01, n=10). (E) CAV1 protein is reduced in 
the jejunum of CAV1IEC-KO mice as measured by western blot and normalized to #-tubulin. 
Data are expressed relative to CAV1fl/fl WT CAV1 protein, n=3 western blots, 5 WT and 5 
IKO mice per blot, Student’s t-test, * signifies p<0.05. (F) Representative western blot. Body 
mass of male (G) and female (H) mice; mice were fed a low-fat (10%) or high-fat (60%) diet 
starting at 10 wk (n=10$15). HFD mice had significantly higher body mass than LFD mice, 
but loss of intestinal epithelial cell CAV1 did not affect body mass (mean ± s.e.m, linear 




3C) and not expressed in the jejunum of negative control CAV1KO mice (data not shown). Cav2 
mRNA is also decreased in CAV1IEC-KO mice, which have 75% less Cav2 mRNA relative to 
CAV1fl/fl WT mice (Student’s t-test, p =0.01) (Fig. 3d)(148, 149). Western blot shows CAV1 
protein expression is 55% lower in CAV1IEC-KO mouse jejunum than in CAV1fl/fl WT littermates 
(Fig. 3E) and that CAV1 is lost in the jejunum of negative control CAV1KO mice (Fig. 3F). 
Loss of intestinal epithelial CAV1 does not affect body mass or glucose metabolism 
High-fat diet (HFD) increases the body mass of male and female mice relative to mice 
fed a low-fat diet (LFD), but CAV1IEC-KO does not protect against diet-induced obesity (16 wk on 
diet, 22 wk old, linear regression, males: F=37.7689, p<0.0001 for diet, females: F=33.8792, 
p<0.0001 for diet) (Fig. 3G,H). Fasting plasma glucose (Fig. S1A), glucose tolerance (Fig. 
S1B,C), and insulin tolerance (Fig. S1D) are similarly unaffected by genotype. Thus, neither body 
mass or glucose metabolism influence the following changes in lipid metabolism.  
Deletion of intestinal epithelial CAV1 alters cholesterol levels 
Deletion of CAV1 in the intestinal epithelia results in changes in fasting and postprandial 
circulating total and lipoprotein cholesterol, especially when mice were challenged by 16 wk  
Figure S1 (next page). Glucose metabolism is unaltered in CAV1IEC-KO mice. (A) Fasting 
blood glucose is elevated in male and female mice fed HFD relative to mice fed LFD 
similarly in CAV1IEC-KO (IKO) mice and WT littermates (mean ± s.e.m, n=6$10, two-way 
ANOVA, p<0.05, groups with different brackets show significant effect of diet, groups with 
different letters are significantly different by post hoc testing). There were no differences in 
blood glucose between CAV1IEC-KO (IKO) and WT mice during (B) IP or (C) oral glucose 
tolerance tests or (D) insulin tolerance test. Data are shown as mean ± s.e.m, n=7$14, one- or 
two-way repeated measures ANOVA.  
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HFD. Compared to CAV1fl/fl WTs, male CAV1IEC-KO mice have a greater increase in total and 
esterified cholesterol upon HFD treatment relative to LFD controls (increase in total cholesterol: 
62.9 mg/dl CAV1IEC-KO vs. 24.3 mg/dl WT, two-way ANOVA, effect of diet: F(1,24)=8.055, 
p=009; increase in esterified cholesterol: 54.4 mg/dl CAV1IEC-KO vs. 19.5 WT mg/dl; two-way 
ANOVA, effect of diet: F(1,23)=7.610, p=.01) (Fig. 4A). A similar trend for greater total 
cholesterol is observed in postprandial male mice maintained on chow diet (CD), but only free 
cholesterol is significantly elevated by these conditions (34.6 mg/dl WT vs. 49.1 mg/dl CAV1IEC-
KO increase, Student’s t-test, p<0.05) (Fig. 4C). It is well established that plasma lipids can show 
sexual dimorphism; here the effects of intestinal CAV1 on plasma cholesterol are sexually 
dimorphic: CAV1fl/fl WT females have greater HFD-associated elevations in total cholesteroliui8 
(WT: 55.1 mg/dl; CAV1IEC-KO: 10.8 mg/dl increase, two-way ANOVA, effect of diet, 
F(1,26)=5.881, p=0.02), free cholesterol (WT: 10.9 mg/dl, CAV1IEC-KO: 1.7 mg/dl increase, two-
way ANOVA, effect of diet, F(1,26)=5.075, p=0.03), and esterified cholesterol compared to 
CAV1IEC-KO females (WT: 44.3 mg/dl, IKO: 9.2 mg/dl increase, two-way ANOVA, effect of diet, 
F(1,26)=4.707, p=0.04) (Fig. 4B). 
 
Intestinal epithelial CAV1 deletion protects against HFD-induced LDL cholesterol increase 
Male CAV1IEC-KO mice are protected against the HFD-associated increase in fasted (4 hr) 
plasma low-density lipoprotein cholesterol (LDL-C) seen in CAV1fl/fl WT littermates (HFD WT: 
35.5 mg/dl, 5.5 mg/dl greater than LFD; HFD CAV1IEC-KO: 23.7, 6.3 mg/dl less than LFD) (two-
way ANOVA, significant interaction between diet and genotype, F(1,24)=5.261, p=0.03) (Fig. 
5A), though female mice do not exhibit this protection (Fig. 5B). Conversely, postprandial LDL-
C is elevated in male CAV1IEC-KO mice (23.4 mg/dl) compared to WT (16.1 mg/dl) (Student’s t-
test, p<0.05) (Fig. 5C). HDL-C is also altered in CAV1IEC-KO mice, as female mice have a greater 
HFD-induced increase in HDL-C relative to LFD in CAV1IEC-KO mice (13.3 mg/dl for males, 17.1 
mg/dl females) compared to WT (9.6 mg/dl for males, 0.2 mg/dl for females) (two-way ANOVA,  
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Figure 4. Loss of CAV1 in the intestinal epithelia alters plasma cholesterol levels. (A) In 
male mice, total and esterified plasma cholesterol are elevated by HFD in WT, but not 
CAV1IEC-KO (IKO), mice following a 4 hr fast (n=5$8). (B) Conversely, for female mice, total, 
free, and esterified plasma cholesterol are elevated by HFD in 4 hr fasted CAV1IEC-KO, but not 
WT, mice (n=8$9). (C) Post-prandial male CAV1IEC-KO mice fed CD have greater plasma free 
cholesterol mice than WT (n=6$8). Data are mean ± s.e.m, two-way ANOVA, * signifies 
p<0.05, groups with different brackets show an effect of diet, groups with different letters are 




Figure 5. Lipoprotein cholesterol levels are affected by loss of CAV1 in the intestinal 
epithelia. Male CAV1IEC-KO (IKO) mice are protected from HFD-induced increase in fasted 
plasma LDL cholesterol (n=6$10, mean ± s.e.m, two-way ANOVA, significant interaction 
between diet and genotype) (A), but female mice are not (n=8$9) (B). Female IKO, but not 
WT, mice have higher fasted plasma HDL cholesterol on HFD than LFD (mean ± s.e.m, two-
way ANOVA, groups with different letters are significantly different by post hoc testing). (C) 
CAV1IEC-KO mice on CD have higher post-prandial plasma LDL cholesterol than WT mice 
(mean ± s.e.m, Student’s t-test, * signifies p<0.05, n=6$9). 
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significant effect of diet F(1,28)=9.516, p=0.005, and interaction between diet and genotype 
F(1,28)=5.684, p=0.024) (Fig. 5A,B). 
Intestinal epithelial CAV1 deletion increases plasma free fatty acids 
Loss of intestinal epithelial CAV1 increases plasma non-esterified fatty acids (NEFA) in 
fasted male HFD CAV1IEC-KO mice (1.43 mmol/L) compared to HFD CAV1fl/fl WT littermates 
(0.94 mmol/L) (two-way ANOVA, effect of diet, F(1,23)=13.15, p=0.0014) (Fig. 6A). NEFA are 
also greater in postprandial CD-fed male CAV1IEC-KO mice (0.42 mmol/L) than WT mice (0.27 
mmol/L) (Student’s t-test, p<0.05)(Fig. 6C). Moreover, serum NEFA decreases less in CD-fed  
male CAV1IEC-KO mice upon feeding (0.44 fold-decrease) than WT male mice (0.83 fold-
decrease) (Student’s t-test, p<0.05). 
Figure 6 (next page). Intestinal CAV1 deletion alters circulating FFA but not TG. (A) In 
male mice, plasma NEFA are higher in HFD fed CAV1IEC-KO (IKO) mice than WT mice 
(means with different letters are significantly different by post hoc testing, 4 hr fast, n=5$8, 
mean ± s.e.m, two-way ANOVA, * signifies p<0.05). (B) Female mice showed no changes in 
fasted plasma TG or NEFA (n=8$9). (C) NEFA are also higher in postprandial plasma of 
male CD CAV1IEC-KO mice compared to WT controls and (D) show a greater fold decrease 
upon feeding relative to fasting (n=6$8, mean ± s.e.m, student’s t-test, * signifies p<0.05). (E) 
Lipids measured by HPLC in plasma of male mice fasted 4 hr. There are significant effects of 
diet for all and, for palmitoleic and palmitic acid, the interaction between diet and genotype 
(n=6, mean ± s.e.m, two-way ANOVA, means with different letters are significantly different 
by post hoc testing, means with different brackets show only a diet effect). (F) Lipids 
measured by HPLC in liver of male mice fasted 4 hr (n=5, mean ± s.e.m, student’s t-test, * 
signifies p<0.05). (G) Cholesterol oleate measured by HPLC in white adipose tissue of male 






To investigate changes in the levels of specific species of plasma NEFA and cholesterol 
esters we performed a lipidomics study. Using HPLC, we measured the relative levels of several 
major plasma lipids including 8 FA species, free cholesterol, two cholesterol esters (-oleate and -
palmitate), and 5 putative lysophospholipids in the plasma of CAV1IEC-KO and CAV1fl/fl WT male 
mice (16 wk HFD or LFD, 26 wk old, 4 hr fast). Strikingly, palmitoleic acid (16:1) is altered in  
the same pattern by diet and genotype as total NEFA (two-way ANOVA, effect of diet, 
F(1,20)=41.70, p<0.0001, effect of genotype, F(1,20)=5.438, p=0.03) (Fig. 6E). Similarly, 
palmitic acid (16:0) is significantly affected by both diet and the interaction between diet and 
genotype (two-way ANOVA, diet effect: F(1,20)=10.77, p=0.0037; interaction effect 
F(1,20)=5.388, p=0.031) (Fig. 6E). Stearic acid (18:0) is significantly elevated by HFD, 
compared to LFD, in CAV1IEC-KO mice (two-way-ANOVA, F(1,20)=11.95, p=0.0025) (Fig. 6E). 
Oleic acid (18:1) and linolenic acid (18:3) are both higher in LFD than HFD fed mice (diet effect 
found by two-way-ANOVA, oleic acid: F(1,20)=7.664, p=0.0119, linolenic acid: F(1,20)=28.72, 
p<0.0001) (Fig. 6E). Neither diet nor genotype affects any of the other FA measured (22:6, 20:4, 
and 18:2). In sum, palmitoleic, palmitic, stearic, and oleic acid may contribute to the observed 
elevation of total NEFA in LFD mice compared to HFD mice. 
  As described above, cholesterol assay kits found that diet affects total and esterified 
plasma cholesterol in CAV1IEC-KO mice (Fig. 4). HPLC analysis identified a direct contribution of 
free cholesterol (two-way ANOVA, effect of diet, F(1,20)=8.693, p=0.008) and cholesterol 
palmitate (two-way ANOVA, effect of diet, F(1,20)=4.800, p=0.04), which are both increased by 
HFD (Fig. 6E). Finally, one putative lysophospholipid (peak 10) which could not be identified 
with standards is also increased by HFD (two-way ANOVA, effect of diet, F(1,20)=33.25, 
p<0.0001) (Fig. 6E). 
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 To investigate the mechanism underlying the elevation in plasma NEFAs in male HFD 
CAV1IEC-KO relative to male HFD WT mice, liver and white adipose lipids were also measured by 
HPLC in male HFD mice. Four of the fatty acids that were decreased in CAV1IEC-KO plasma, 
palmitoleic, palmitic, stearic, oleic, and linolenic acids, were also significantly decreased in the 
liver (Fig. 6F). It is striking that all of the fatty acids that are decreased in the liver of CAV1IEC-KO 
mice, with the exception of stearic acid, have a trend to be increased in the plasma where total 
NEFAs are increased. Additionally, hepatic cholesterol is lower in HFD CAV1IEC-KO mice (Fig. 
6F). No differences were observed in triglycerides, cholesterol esters, or, similar to plasma, 22:6, 
20:4, or 18:2 in the liver of HFD mice (data not shown). Of all these lipids, only cholesterol 
oleate varied in the white adipose tissue, showing a decrease in CAV1IEC-KO mice (Fig. 6G; data 




The global obesity epidemic has caused an explosion in the prevalence of metabolic 
diseases such as type II diabetes and cardiovascular disease. Intensive efforts have focused on the 
identification of therapeutic targets to better prevent and treat metabolic syndrome. Previous work 
had identified functional roles of adipocyte and endothelial CAV1 in susceptibility to diet-
induced obesity (116), insulin resistance (120), and atherosclerosis (121). In this study we 
expanded upon these findings by visualizing the localization of enterocyte Cav1 and caveolar 
endocytosis and identifying a role for CAV1 in the intestinal epithelia in the regulation of plasma 
FA and LDL cholesterol, lipids that contribute to the development of several metabolic diseases. 
Although it is known that CAV1 is expressed in the intestinal epithelium (126), the 
intracellular localization of this protein has remained ambiguous: lateral PM localization in Caco-
2 colon-derived cells (150); either the brush border or lateral and basolateral PM localization in 
Caco-2 cells depending on the fix, permeabilization method, and antibody used (126); lateral 
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membrane of T84 colon derived cells (127); cytoplasmic vesicles and lateral PM at adherens and 
tight junctions in mouse jejunum (129); low levels on the mouse small intestine brush border 
(130); cytoplasmic vesicles in mouse colon (132); deep apical tubules in pig small intestine (151); 
human small intestine cytoplasmic vesicles (128); and apical PM and cytoplasmic vesicles in C. 
elegans intestine (152). Here our in vivo study reveals that Cav1 localizes asymmetrically to 
lateral and basolateral enterocyte PM in larval zebrafish. CAV1 is a FA- and cholesterol-binding 
protein and caveolae can only form in lipid-rich PM regions. Although these lipid-rich regions do 
form on the enterocyte brush border (153), this membrane has a lipid composition distinct from 
the lateral and basolateral PM, with more glycolipids and less cholesterol and sphigomyelin 
(154). It is possible that the relative scarcity of cholesterol in the brush border excludes CAV1 
and caveolae from this PM. Unfortunately, the cellular localization of mouse CAV1 in the 
intestinal epithelia could not be determined due to non-specific antibody binding which we 
observed in enterocytes.  
Fluorescently labeled endocytic cargos are valuable tools to visualize various types of 
endocytosis in cultured cells (138, 155). Here, we extended this technology to image the 
enterocyte PM regions that likely perform caveolae-mediated endocytosis in vivo. The results 
suggesting that caveolae-mediated endocytic activity in enterocytes is asymmetric points to a role 
for caveolae in vesicular transport between enterocytes and the body, but not the intestinal lumen. 
The optical clarity of larval zebrafish and advances in mouse vital imaging present the 
opportunity to extend this technique to investigations of caveolae- and clathrin-mediated 
endocytosis in a multitude of tissues in the context of health or disease.  
 Prior studies have reported increased fasting plasma cholesterol in male CAV1KO mice, 
largely consisting of elevations in VLDL and LDL cholesterol resulting from adipocyte lipid 
storage defects and decreased aortic and hepatic LDL uptake (117, 118). Our studies find that the 
intestinal epithelium does not mediate these changes, as we did not observe differences in plasma 
cholesterol or cholesterol palmitate in CAV1IEC-KO mice. However, we did find that LDL 
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cholesterol levels were increased postprandially and decreased during fasting (when hepatic 
cholesterol is also decreased) in male HFD CAV1IEC-KO mice; this is opposite of the pattern 
observed in CAV1KO mice. Another striking observations is that male CAV1IEC-KO mice have 
increased fasting plasma NEFA (HFD), mirrored by decreases in several hepatic fatty acids, and 
decreased postprandial NEFA (CD). The literature regarding the effect of total body CAV1 
deletion on circulating FFA is conflicting, with reports of higher fasting and postprandial FFA 
(116, 124), decreased fasting FFA (123), or no changes (118). 
First, we hypothesized that the changes in LDL cholesterol and FFA could be mediated 
by the cluster of differentiation 36 scavenger receptor (CD36). CD36 delays LDL clearance 
(156), so impairment of its function in CAV1IEC-KO mice could accelerate LDL clearance, causing 
the observed decrease in fasting LDL cholesterol. Increased postprandial LDL cholesterol could 
also be explained, as CD36 facilitates cellular cholesterol uptake (157). Additionally, FFA could 
be increased due to impaired CD36 localization and function, since CD36 facilitates FA uptake 
(157, 158) and its deletion increases serum FFA (159). CD36 is highly expressed in the proximal 
intestine (160) and CAV1 is necessary for CD36 to properly localize to the PM of mouse 
Figure S2 (next page). (A) Deletion of CAV1 does not affect CD36 localization in the 
intestinal epithelia. Representative images of CD36 immunofluorescence in the jejunum of 
HFD treated CAV1IEC-KO and WT littermate mice show localization to the brush border and 
small, apical punctae of enterocytes. Mice were fasted 4 hr, jejunum was fixed in 4% PFA 
overnight at 4°C, imbedded in OCT, cut into 10 µ cryosections, treated with Diva Decloaker 
antigen retrieval, probed with primary anti-CD36 (AF2519, R&D Systems) and secondary 
donkey-anti-goat (A-11055, Life Technologies), and imaged on a Leica SP-5 confocal 
microscope with a 63x oil immersion objective. (B) Plasma albumin is not affected by diet 
or genotype in male CAV1IEC-KO (IKO) and WT littermates fed LFD or HFD. Mice were 
fasted 4 hr, plasma was collected by cardiac puncture, and albumin was measured in 




embryonic fibroblasts (161). Therefore, we speculated that CD36 PM localization and or 
expression may be dysregulated in CAV1IEC-KO mice. However, contrary to the previous findings 
in mouse embryonic fibroblasts, no change in CD3 localization was observed in the intestinal  
epithelia of HFD treated CAV1IEC-KO mice (Fig. S2A) and no decrease in mRNA or protein 
expression were observed (data not shown). In support of this conclusion, it would be expected 
that hepatic cholesterol would increase if the CD36-medated LDL clearance delay was perturbed, 
but instead HPLC analysis found a decrease in hepatic cholesterol.  
Second, changes in circulating FFA in CAV1IEC-KO mice could be mediated by changes in 
intestinal albumin uptake. Circulating FFA are transported by albumin, as much as 18% of which 
is absorbed and catabolized by the intestine (162). Indeed, we showed that Alexa Fluor-albumin 
is internalized by caveolae on the basolateral PM of enterocytes. If this were true a concomitant 
increase in plasma albumin would be expected, however this was not observed (Fig. S2B). As 
circulating albumin levels are tightly regulated, this hypothesis cannot be ruled out lacking direct 
measurement of albumin flux from the liver. Nonetheless, in further support of our conclusion, 
increased postprandial plasma lipids likely do not result from altered intestinal processing 
because no changes in serum NEFA or TG were observed by an oral lipid tolerance test (Fig. S3).  
Third, we hypothesized that CAV1IEC-KO mice may have decreased intestinal insulin 
signaling, and thus insulin stimulated plasma FA uptake, underlying the observed increase in 
circulating NEFA. This hypothesis is supported by the fact that insulin signaling is present in the 
intestine (163), the insulin receptor localizes to caveolae (164), and that global CAV1 knockout 
mice are insulin resistant (120). Substantiating this hypothesis insulin receptor mRNA is 
significantly decreased in the jejunum of CAV1IEC-KO mice compared to controls (Fig. S4), but no 
change in insulin receptor subunit β protein was observed by Western blot (data not shown). 
Importantly, there may be a non-IEC autonomous mechanism (insulin signaling or otherwise) by 
which hepatic fatty acid uptake is decreased or secretion is increased leading to the observed  
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Figure S3. Lipid tolerance test show no change 
in serum TG or NEFA in CAV1IEC-KO mice 
following emulsified lipid gavage. Male and 
female CAV1IEC-KO (IKO) and WT littermates 
were fed CD and fasted 16 hr prior to gavage 
(n=7$9).  
Figure S4. Deletion of Cav1 from the mouse 
intestinal epithelium (CAV1IEC-KO) decreases 
insulin receptor expression. Insulin rector 
mRNA is decreased in the jejunum of 
CAV1IEC-KO mice compared to wild type (WT) 
littermates. Means, 2-way ANOVA, significant 




decrease in several hepatic fatty acids and corresponding increase in circulating NEFA. Similarly, 
loss of CAV1 in IEC may underlie a non-cell autonomous mechanism by which hepatic  
cholesterol is decreased, limiting the amount of LDL that can be secreted, causing the decrease in 
LDL-C observed in CAV1IEC-KO mice. 
 HPLC determined that palmitoleic and palmitic acid contribute to the overall increase in 
fasting NEFA observed in HFD CAV1IEC-KO mice.  Palmitoleic acid is an omega-7 mono-
unsaturated FA that is enriched in endothelial caveolae (165). If palmitoleic acid is also 
preferentially carried in enterocyte caveolae, it follows that loss of CAV1 could result in 
decreased palmitoleic acid uptake, and the observed plasma elevation. Further investigation of the 
detailed mechanism would be of interest since palmitoleic acid is a bioactive lipid: dietary 
supplementation has plasma lipid lowering, anti-diabetic, and anti-inflammatory activity (166), 
but elevated plasma palmitoleic acid is correlated with increased heart failure (167) and non-
alcoholic fatty liver disease (168). It is possible that no influence of genotype on plasma 
palmitoleic acid levels in LFD mice was found simply because it comprises a much smaller 
proportion of the diet (0.04% of total LFD vs. 0.44% of total HFD by mass). Caveolae are also 
enriched in palmitic acid (169) so plasma palmitic acid may in higher in CAV1IEC-KO than WT 
mice due to the mechanism proposed above. Since CAV1 is palmitoylated (170), decreased 
activity in this pathway may contribute to the plasma palmitic acid elevation.  
 Finally, the sexual dimorphism observed in the changes in plasma lipids in CAV1IEC-KO 
mice must be addressed. It is well established that male and female animals have metabolic 
differences; in C57BL/6J mice, this includes differences in lipid and fatty acid metabolism gene 
expression in multiple tissues (171). Moreover, sex-specific metabolic differences have been 
observed previously in global CAV1 KO mice: decreased body mass on chow diet compared to 
WT in male, but not female, mice and increased food intake relative to WT in female, but not 
male, mice (116). However, neither sex had increased circulating free fatty acids compared to 
WT, and LDL cholesterol was only measured in male mice, where it was increased compared to 
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WT (116). In contrast to this previous study, we report that CAV1IEC-KO male, but not female, 
mice were protected from the HFD-induced increase in plasma LDL cholesterol observed in WT. 
Although the mechanism for this difference is unknown, it is possible that sexually dimorphism 
in estrogen receptor signaling underlies this difference. When estrogen binds the estrogen 
receptor α (ERα) transcription factor, ERα activates transcription of the LDL receptor (LDLR), 
which takes up LDL from the circulation (172). CAV1 has been shown to potentiate the action of 
ERα in cultured cells (173). Additionally, female mice of mixed genetic background (129/Pas x 
C57BL/6J, ~90% C57BL/6J) have higher Ldlr and Cd36 hepatic gene expression compared to 
males (174). Therefore, since estrogen levels are higher in females, differences in estrogen-
stimulated LDLR transcription and subsequent cellular uptake may underlie the observed sex-
specific differences in LDL cholesterol in CAV1IEC-KO mice. Furthermore, female CAV1IEC-KO 
mice had significantly increased HDL cholesterol on HFD compared to LFD; this difference was 
not observed in WT females, and the trend was non-significant in males. These findings are 
consistent with Link et al.’s report that mice with two X chromosomes have higher HDL 
cholesterol levels than XY mice (175). The observed sexual dimorphism does not preclude 
intestinal epithelial CAV1 as a potential therapeutic target for metabolic disease as many 
pharmaceuticals currently in use have sexually dimorphic actions, including the LDL cholesterol 
lowering drug fenofibrate (176). Nor does the modest decrease in LDL cholesterol preclude 
intestinal epithelial CAV1 as a therapeutic target, since even a 1% reduction in LDL cholesterol 
leads to a 1% decrease in cardiovascular disease risk (177). 
In conclusion, this study demonstrated that CAV1 localizes to, and caveolar endocytosis 
occurs on, the lateral and basolateral PM of intestinal enterocytes. Although the detailed cellular 
mechanism remains to be elucidated, it is clear that CAV1 on enterocyte basolateral membranes 
influences circulating levels of LDL cholesterol and NEFA, specifically palmitoleic and palmitic 
acid. Elevated plasma FA and LDL cholesterol are associated with metabolic disease, including 
type II diabetes and cardiovascular disease. The results of this study indicate that CAV1 in the 
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intestinal epithelium may serve as a therapeutic target to lower circulating FA and LDL 





Generation of transgenic zebrafish 
Zebrafish research was approved by the Carnegie Institution Department of Embryology 
IACUC Committee (protocol #139). Zebrafish were housed at 28°C with a 14:10 light:dark cycle. 
Tg(hsp70l:cav1-eGFP) zebrafish were created with the tol2-Gateway system (178). Zebrafish 
cav1 was cloned from Image Consortium plasmid #3719638 (fb95c12) and Gateway cloning 
constructed hsp70l:cav1-eGFP: the zebrafish heat shock cognate 70-kd protein, like (hsp70l) 
promoter driving cav1 tagged with eGFP (provided by Chi-bin Chien). This plasmid was injected 
with tol2 transposase for genome integration with a microforged glass needle (P-97 
Flaming/Brown micropipette puller, Stutter Instruments, Novato, CA) connected to a nitrogen gas 
pressure injector (PLI 100, Harvard Apparatus, Cambridge, MA) into 1−2 cell zebrafish embryos 
(AB background). F0 larvae were heat shocked (45 min, 37°C, in 15 ml embryo media (EM)) at 6 
day post-fertilization (6 dpf) and screened for mosaic Cav1-eGFP expression 4−6 hours later. 
Three independent stable lines were established and all further experimentation was undertaken in 
stable transgenic animals.  
 
Live imaging of zebrafish larvae and quantification of fluorescence  
Approximately 24 hr prior to imaging larvae were heat shocked as described above to 
induce Cav1-eGFP expression. Larvae were anesthetized with tricaine (Sigma-Aldrich, St. Louis, 
MO) and mounted in 3% methyl cellulose (Sigma-Aldrich, St. Louis, MO) under a coverslip (28). 
Live Tg(hsp70:cav1-eGFP) larvae were imaged on a SP-2 confocal microscope (Leica 
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Microsytems, Deerfield, IL) with an argon laser under a 63x oil immersion objective. Images 
were collected as 12 bit and analyzed with Metamorph software (Molecular Devices, Sunnyvale, 
CA). Regions of the brush border, lateral, and basolateral PM, as well as intracellular regions, 
were outlined for quantification of mean fluorescence intensity (3 regions of interest for each 
cellular area, 3 images per fish, 3 fish per experiment, for a total of 3 experiments or 9 fish). 
 
Immunofluorescence and Electron Microscopy 
Larval (6 dpf) zebrafish and intestines from adult zebrafish and were collected for IF and 
EM. Prior to euthanasia adult fish were fed shellfree Artemia (decapsulated, non-hatching; INVE 
Aquaculture, Ogden, UT) and Hikari Micropellets (Aquatic Eco-systems, Apopka, FL) twice 
daily; adults used for EM fed on a lipid-rich, hard-boiled chicken egg yolk for 1 hr ad lib; larvae 
studied were lecithotrophic (6 dpf) and thus were not provided exogenous food. IF samples were 
fixed in 4% paraformaldehyde in PBS overnight at 4°C, embedded in paraffin and 10 µ slices 
were mounted on positively charged slides. IF was carried out on zebrafish using an antibody to 
CAV1 (#610059, BD Transduction Labs, Lexington, KY) and Alexa Fluor 488 goat-anti-rabbit 
IgG (#A-11008, Invitrogen, Carlsbad, CA). Completed IF sections were mounted with 
Fluoromount-G (SouthernBiotech, Birmingham, AL) and imaged with a 63x oil immersion 
objective and an argon laser on an SP-5 confocal microscope (Leica Microsytems). EM samples 
were fixed in 3% glutaraldehyde (Electron Microscopy Sciences, Hatfield, PA) and 1% 
formaldehyde, post-fixed in reduced osmium (Electron Microscopy Sciences), stained with uranyl 
acetate (Fisher Scientific), embedded in Epon 812 resin (Ladd Research Industries, Williston, 
VT), and imaged on a Technai-12 electron microscope (FEI, Hillsboro, OR) with a 794 multiscan 
camera (Gatan, Pleasanton, CA). Mouse CAV1 IF was attempted on paraffin sections and 
cryosections of jejunum collected after a 4 hr fast, but non-specific fluorescence was observed in 
enterocytes, even in the negative control, global CAV1 KO mice. The antibodies tested were: BD 
Biosciences/Transduction labs #610059, 610057 and 610406, Santa Cruz Biotechnology #sc-894, 
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Abcam #ab2910, and Cell Signaling # 3238s. The antigen retrieval methods tested were Tris-
EDTA buffer, sodium-citrate buffer, and Diva Decloaker (Biocare Medical, Concord, CA).  
 
Imaging fluorescently labeled endocytic cargos in vivo 
WT Larvae (6 dpf) were anesthetized in tricaine and mounted in 1.2% low melt agarose 
(Sigma-Aldrich) in EM. A microforged glass needle was loaded with (4,4-difluoro-4-bora-3a, 4a-
diaza-S-indacene)-l-threo-lactosylceramide (BODIPY-l-LacCer)) (provided by David Marks) or 
BODIPY-d-erythro-LacCer (#895279, Invitrogen) at a concentration of 2.5 µg/µl in 30% ethanol 
and 70% embryo media, or Alexa Fluor-594-albumin (#A13101, Fisher Scientific, Pittsburgh, 
PA) at a concentration of 5 µg/µl in PBS. A nitrogen-pressured injection rig was used to inject 2 
nl to the basolateral side of the intestine or into the intestinal lumen. Larvae were freed from the 
agarose, allowed to recover for 30 min (LacCer) or 1 hr (albumin) while swimming freely, re-
anesthetized, mounted in 3% methyl cellulose under a coverslip, placed on ice to stop endocytosis 
(179), imaged, and the same sample size was analyzed with Metamorph software as described 
above. 
 
Breeding CAV1IEC-KO mice 
Mouse research was approved by the Carnegie Institution Department of Embryology 
IACUC Committee (protocol #156). Mice were housed at 20-21°C with a 12:12 light cycle. Mice 
with a floxed Cav1 allele (provided by Michael Elliot) (146) were crossed with Tg(Vil-
cre)997Gum/J mice (#004586, Jackson Labs, Bar Harbor, ME) which express Cre recombinase 
specifically in the intestinal epithelium, producing mice lacking Cav1 specifically in the intestinal 
epithelium (CAV1IEC-KO)(back crossed to C57BL/6 6 times) (Fig. 1A). All experiments were 
performed with CAV1IEC-KO vs. Cav1fl/fl (WT) littermates. 
Mice were genotyped for floxed Cav1 (350 bp band following PCR with F1:TTC TGT 
GTG CAA GCC TTT CC and R1:GTG TGC GCG TCA TAC ACT TG) and Vil-Cre PCR (1,100 
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bp band following PCR with F: GTG TGG GAC AGA GAA CAA ACC and R:ACA TCT TCA 
GGT TCT GCG GG). The occurrence of Cre recombination in the intestine of CAV1IEC-KO mice 
was verified by the presence of a 350 bp band (F1 primer above, R2: GGG GAG GAG TAG 
AAG GTG GC) (146) on genomic DNA isolated from whole jejunum segments by NaOH 
extraction (180). Cav1tm1Mls (CAV1IEC-KO) mice lacking functional Cav1 in all tissues were used as 
controls (#007083, Jackson Labs, Bar Harbor, ME). 
 
RT-PCR 
Cav1 and Cav2 mRNA levels were measured in whole jejunum by RT-PCR: mRNA was 
isolated with Trizol (Invitrogen), cDNA was synthesized with AMV reverse transcriptase (New 
England Biolabs, Ipswich, MA), and RT-PCR was run with the PrimePCR SYBR Green assay for 
mouse Cav1 and Cav2 according to the manufacturer’s instructions (#100-25636, BioRad 
Laboratories, Hercules, CA).  
 
Western Blot 
CAV1 protein was measured by Western blot as previously described (181). Briefly, 
cytosolic fractions of jejunum were run on denaturing SDS-Page gels with a Mini-Protean system 
(BioRad Laboratories), transferred to nitrocellulose, blocked with blocking grade blocker 
(BioRad Laboratories), and probed with antibodies to CAV1 (#610059, BD Transduction Labs, 
Lexington, KY), α-tubulin (#T6199, Sigma-Aldrich), goat-anti-rabbit IgG-HRP (#170-6515, 
BioRad Laboatoris), and goat-anti-mouse IgG-HRP (#170-6516, BioRad Laboratories). Protein 
expression was imaged by chemiluminescence (SuperSignal West Pico Chemiluminescent 
Substrate, Pierce, Rockford, IL). Data from 3 western blots, with 5 WT and 5 IKO mice each, 





Upon weaning, mice were fed CD ad lib (#7012, Harlan Teklad, Fredrick, MD). At 10 
wk of age, mice were either continued on CD, or fed a 60% HFD or 10% fat, nutrient-matched 
LFD (#D12492 and #D12450J respectively, Research Diets, New Bruswick, NJ) ad lib. Mice fed 
HFD and LFD were massed weekly until euthanasia at 26 wk; n=10−15 mice per diet.  
 
Plasma cholesterol and lipid analysis  
Mice were euthanized by CO2 inhalation and blood was collected by cardiac puncture. 
Serum was collected by centrifugation (15 min, 2,000 x g, 4°C) after allowing blood to clot on 
ice. Plasma was collected by centrifugation (15 min, 2,000 x g, 4°C) in EDTA-treated tubes 
(Sarstedt, Numbrecht, Germany). All serum and plasma samples were snap frozen and stored at -
80°C. Kits were used to measure total cholesterol (Infinity Total Cholesterol, Fisher Scientific), 
free cholesterol (Free Cholesterol E, Wako Diagnostics, Richmond, VA), HDL cholesterol (HDL-
C E, Wako Diagnostics), LDL cholesterol (LDL-C Reagent L-type, Wako Diagnostics), NEFA 
(HR Series NEFA-HR(2), Wako Diagnostics), and TGs (Infinity Triglycerides, Fisher Scientific) 
according to the manufacture’s directions. For HFD and LFD male mice n=5−8, for HFD and 
LFD female mice n=8−9; and for CD male mice, n=6−8. 
 
HPLC 
HPLC was implemented to measure levels of specific plasma lipids. Lipids were 
extracted from plasma (50 µl), liver (10-50 mg), and white adipose tissue (15-40 mg) using a 
modified Bligh-Dyer procedure (28), dried under vacuum, and resuspended in the injection 
solvent HPLC-grade 2-propanol.  
HPLC was performed using a LPG-3400RS quaternary pump, WPS-3000TRS 
autosampler, TCC-3000RS column oven, Accucore C18 column (150 x 3.0 mm, 2.1 µm particle 
size) and Dionex Corona Veo charged aerosol detector (all from Thermo Scientific). Lipids were 
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separated over 80 min in a multistep gradient as follows: 0-5 min at 0.8 mL/min in 98.0% mobile 
phase A (methanol-water-acetic acid, 750:250:4) and 2.0% mobile phase B (acetonitrile-acetic 
acid, 1000:4), 5-35 min at 0.8-1.0 mL/min, 98.0-30% A, 2.0-65.0% B, and 0-5.0% mobile phase 
C (2-propanol), 35-45 min at 1.0 mL/min, 30%-0% A, 65.0%-95.0% B, and 5.0% C, 45-73 min at 
1.0 mL/min, 95.0-60.0% B and 5.0-40.0% C, and 73-80 min at 1.0 mL/min, 60.0% B, and 40.0% 
C (adapted from pers. corr. with Marc Plante, Thermo Scientific). Following the analytical 
portion of the gradient, the column was washed for 20 min with 100% mobile phase C at 0.4 
mL/min, then returned to 98% A and 2% B at 0.8 mL/min for re-equilibration. Injection volume 
was between 5 and 25 µL and was adjusted for each sample to produce optimum peak shape for 
quantitation. The autosampler tray was maintained at 20.0oC and the column oven temperature at 
40.0oC.  
Chromatographic peaks were identified by comparison with standards (Sigma-Aldrich). 
Early-eluting peaks not identified as FA were confirmed as polar lipids by acetone precipitation 
(adapted from (95)), and based on their retention times when compared with those of polar lipid 
standards, were determined to most likely be lysophospholipids (data not shown). Quantitative 
comparison of the relative amounts of lipid species of interest was performed blinded using 
Chromeleon 7.2 (Dionex, Sunnyvale, CA). Peak baselines were drawn manually and areas (in 
picoamperes (pA)*min) were determined automatically. For plasma samples, all peak areas were 
divided by the area of the second lysophospholipid peak in the same sample. This lipid was 
chosen as it varied the least among all of the samples after accounting for injection volume. For 
comparison between samples, lipid amounts are expressed as [peak area (pA*min)]/[area of peak 
2 (pA*min)]. For liver and white adipose samples, all peak areas were normalized to percent of 
total signal to control for unequal extraction efficiencies and differences in starting tissue mass 





Blood glucose was measured in mice fasted 4 hr by tail bleed using a glucometer 
(AlphaTRAK glucose meter, VWR, Radnor, PA) just prior to euthanasia (n=6−10). For IP GTT, 
mice fasted 4 hr were administered 2 g/kg sterilized glucose in water IP and blood glucose was 
measured from the tail vein by glucometer at 0, 15, 30, 60, and 120 min (n=9−14). For OGTT, 
the same dose of sterile glucose was administered by gavage and blood glucose was monitored as 
described (n=7−9). ITT was performed by administering mice IP insulin (#12585-014, Gibco, 
Gaithersburg, MD) at a dose of 0.76 U/kg for LFD mice and 1 U/kg for HFD mice; blood glucose 
was measured as described for GTT (n=7−13). GTT and ITT results were analyzed by two-way, 
and OGTT by one-way repeated measures ANOVA followed by Tukey’s post hoc test. 
 
Lipid tolerance test 
Male and female CAV1IEC-KO and WT littermates were housed on CD until 12 wk old, 
fasted 16 hr, and gavaged with 10 µl/g body mass 20% emulsified Intralipid (soybean oil) 
(Sigma). Serum was collected from tail bleed at 0, 1, 2, 3, and 4 hours post gavage. TGs and 
NEFA were assayed as described above. 
 
Statistics 
Differences in Cav1-eGFP fluorescence intensities were compared with a one-way 
ANOVA followed by Tukey’s post hoc test. Student’s t-test was used to compare endocytic cargo 
membrane fluorescence and RT-PCR measurements of jejunal mRNA. Western blot data from 
each of 3 blots were adjusted by expression of the loading control and expressed relative to WT 
levels, averaged together, and compared by Student’s t-test. Differences in BM were compared by 
linear regression. Plasma lipids identified by HPLC were compared by two-way ANOVA 
followed by Tukey’s post hoc test. Liver and white adipose lipids measured by HPLC were 
compared by Student’s t-test. All data analyzed by ANOVA were first confirmed for 
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homogeneity of variance by Bartlett’s or Brown-Forsythe tests. Statistics were performed with 
Prism software (GraphPad, La Jolla, Ca). 
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CHAPTER 4 – ETHANOL ALTERS DIETARY LIPID 




Potential crosstalk between ethanol metabolism and dietary fatty acid metabolism 
 
Cirrhosis is characterized by advanced steatosis, fibrosis, and inflammation of the liver 
that often leads to liver failure, can progress to hepatocellular carcinoma, and is the twelfth 
leading cause of death in the United States (182). Cirrhosis and the progressively worse 
conditions that lead to it are known collectively as Alcoholic Fatty Liver Disease (AFLD), and 
the progression from simple steatosis (triglycerides as > 5% of the liver mass) to steatohepatitis 
(steatosis with inflammation) to cirrhosis (largely irreversible fibrosis of the liver) is driven in 
part by the accumulation of damage from repeated acute alcohol-induced injuries: Metabolism of 
alcohol in hepatocytes releases toxic byproducts such as acetaldehyde and reactive oxygen 
species, causing inflammation. Ethanol is also associated with mitochondrial stress and reduced 
catabolic capacity – this combined with the fact that ethanol itself can be used to synthesize 
saturated fatty acids leads to hepatic steatosis (183). Prolonged hepatic inflammation can result in 
fibrosis, which occurs when hepatic stellate cells secrete extracellular matrix components into the 
liver in response to tissue damage (184). In studies performed by Lieber et al, hepatic steatosis 
and inflammation were significantly increased in human subjects given large amounts of ethanol 
for just two days (185). Although the role of alcohol overconsumption alone in both acute and 
long-term liver injury has been studied extensively, progression of AFLD does not correlate 
perfectly with the amount or duration of ethanol exposure. Furthermore, the effect of light to 
moderate regular drinking and/or infrequent binge drinking on the progression of non-alcoholic 
fatty liver disease (NAFLD) is poorly understood: it is known that even in a healthy liver ethanol 
promotes storage of dietary fatty acids in hepatocyte lipid droplets over oxidation, but potential 
variations in the effect of ethanol on different fatty acids both in terms of catabolism and 
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partitioning into complex lipids have not been characterized. Since 70% of adults drink at least 
occasionally (NIAAA, 2012), it is important to understand how light and/or infrequent ethanol 
intake may influence both fatty acid metabolism in the absence of chronic disease, and the 
progression of non-alcoholic fatty liver disease. 
 
The zebrafish is an established model system for ethanol research 
Both adult and larval zebrafish metabolize ethanol and can develop hepatic steatosis, 
inflammation, and fibrosis as a result of ethanol exposure (186, 187). They express analogs of 
genes important in ethanol metabolism including adh1 (alcohol dehydrogenase), aldh (aldehyde 
dehydrogenase), and cyp2e1 (a cytochrome P450 family member involved in xenobiotic 
metabolism) (186). Adult male zebrafish raised continuously in a 1% ethanol solution developed 
steatosis or steatohepatitis at 2 weeks, and hepatic fibrosis (collagen accumulation) occurred by 
12 weeks of treatment (188). Larvae also exhibit acute alcohol-associated hepatic steatosis when 
treated with 2% ethanol for >18 hours during the last day of yolk absorption (starting at 4 dpf): 
neutral lipid accumulates in the liver (revealed by Oil red O staining of fixed larvae) and 
hepatomegaly occurs (186). In the three days following this single exposure to ethanol, larvae 
develop liver inflammation (e.g., expression of inflammatory cytokines is increased), oxidative 
stress (shown with the H2CDF ROS reporter and increased expression of sodB and other 
associated genes), hepatic stellate cell proliferation, and increased deposition of the ECM 
components collagen and laminin (186, 187).  
 
Outstanding questions about the influence of ethanol on nutrient metabolism 
Though it has long been known that ethanol influences lipid metabolism by driving 
accumulation of triglyceride in the liver, the specific details of potential interactions between 
ethanol metabolism and lipid metabolism are currently unknown. For example, though it is 
known that ethanol promotes fatty acid synthesis in the liver by activating SREBP-1c	(189), the 
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potential role of specific dietary lipids in alcoholic hepatic steatosis has not been examined. 
Furthermore, as the byproducts of ethanol metabolism globally disrupt function, it is plausible 
that fatty acid metabolism would be disrupted in tissues that metabolize both ethanol and dietary 
nutrients. As described in Chapter 2, a strength of the larval zebrafish model is the ability to use 
the same fluorescent fatty acid reagents as metabolic labels for both live imaging and biochemical 
experiments. Here I have employed this technique to examine the influence of ethanol on both the 
deposition of dietary fatty acids and their products in the liver, and the partitioning of dietary fatty 





Adult zebrafish and larvae were maintained as described in Chapter 2. 
 
Ethanol treatment 
Larval zebrafish were raised to 5 days post-fertilization when their yolk supplies were 
depleted. For all HPLC experiments, larvae were soaked in a solution of 1% ethanol (v/v) in 
embryo media for 20 hours at 25oC (adapted from (186)). Ethanol concentrations were varied for 
confocal imaging experiments. 
 
Fluorescent lipid feeding 
For HPLC, larvae were fed BODIPY FL, -C5, -C12, or –C16 in a 5% chicken egg yolk 
emulsion as described in Chapter 2. In the most recent experiment (Figure 2), TopFluor-
Cholesterol was added to the feed solution as a control for amount eaten and lipid extraction 
efficiency. (TopFluor-Cholesterol is not esterified during the first 18 hours after feeding; later 
time points were not examined (with Jessica Otis)). 
	 106	
Confocal microscopy 
For live confocal imaging of the liver, larvae were fed BODIPY FL-C5 in a 5% chicken 
egg yolk emulsion as described in (28). Imaging was performed as described in Chapter 2. 
 
HPLC-Fluorescence/CAD 
HPLC-Fluorescence/CAD including sample preparation and data analysis was performed 





Larval zebrafish exhibit acute alcohol-induced hepatic steatosis 
 In previously published work, the standard ethanol dosage given to larval zebrafish to 
induce the hepatic injury response is immersion in 2% ethanol from 96 to 120 hpf (hours post-
fertilization) (186, 190-192). This treatment has been useful for some applications such as 
detecting subtle ethanol-associated changes in gene expression (186, 187). However, overnight 
treatment of zebrafish larvae with 2% ethanol also causes gross morphological defects and 
impaired swimming behavior (186), which is a concern in nutritional experiments as the ability of 
the larvae to eat could be affected. Larval zebrafish were immersed overnight (20 hours) in a 
range of ethanol concentrations to identify the lowest ethanol dose that would consistently 
produce acute hepatic steatosis without altering feeding behavior. Following ethanol treatment, 
larvae were given a high-fat meal of chicken egg yolk emulsified with a fluorescently labeled 
fatty acid BODIPY FL-C5), and their livers were imaged by live confocal microscopy. 
Pretreatment with 1-1.5% ethanol resulted in significantly increased liver fluorescence, indicating 
an ethanol-associated increase in hepatic deposition of the fluorescent metabolic products of 
BODIPY FL-C5 (Figure 1). Pretreatment with 1% ethanol did not increase or decrease food  
$-*!
Figure 1. Acute hepatic steatosis is observed in the larval zebrafish after a single 
ethanol treatment. A) and B) Zebrafish larvae were raised to 6 dpf and then treated 
overnight with a range of ethanol concentrations. They were then fed an emulsion of 
fluorescent fatty acid (BODIPY FL-C5). After a 20 hour chase, hepatic steatosis was 
evaluated by live confocal imaging. 400x magnification, scale bars = 10µm. C) The extent 
of hepatic steatosis following ethanol treatment was quantitated by total liver fluorescence. 
Overnight immersion in a 1% or 1.5% ethanol solution before a meal containing fluorescent 
fatty acid resulted in a significant increase in hepatic BODIPY fluorescence (Student’s T-
test).  
$-+!
Figure 2. Overnight treatment with 1% ethanol does not significantly affect feeding. A) 
Zebrafish larvae were raised to 6 dpf, immersed in 1% ethanol for 20 hours, and fed an 
emulsion of BODIPY FL-C5 in a HF/HC meal. Total lipids (including intestinal contents) 
were extracted from groups of 15 larvae and spotted on a TLC plate. B) Total fluorescence 
of each spot in A) was quantitated. There was not a significant difference between ethanol-
treated and untreated groups (Student’s T-test, n = 6).  
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	consumption (Figure 2). 
Additionally, previous work by the Sadler Laboratory has shown that exposure of 
zebrafish larvae to 1% ethanol for 8 hours resulted in a tissue ethanol content of 0.20%, which is 
consistent with the average blood ethanol concentration of a human who has consumed three to 
four servings of alcohol (193, 194). Taken together, these results suggest that acute hepatic 
steatosis (and therefore, alcoholic liver injury) can be modeled in larval zebrafish by treatment 
with ethanol at a dose that does not alter feeding behavior and is physiologically comparable to 
ethanol consumption by humans. Furthermore, these results are the first to demonstrate that 
dietary fatty acids contribute to acute alcohol-induced steatosis. 
 
Preprandial ethanol promotes channeling of dietary fatty acids into phospholipids 
Treatment of 5 dpf larval zebrafish with 1% ethanol overnight before feeding fluorescent fatty 
acids in a HF/HC meal is associated with increased incorporation of BODIPY FL-C5 and 
BODIPY FL-C12 into one or more fluorescent phospholipid species each (Figures 3, 4). The 
specific identities of some of these phospholipids were determined through the LC-MS/MS 
experiments described in chapter 2: significant increases in PC(22:6, BODIPY FL-C5), 
PC(BODIPY FL-C12, 18:1), and PE(BODIPY FL-C12, 16:0) occur in larvae treated with ethanol 
before being fed BODIPY FL-fatty acids. Other BODIPY FL-C12 lipids quantitated in these 
experiments were identified as phospholipids or nonpolar lipids by acetone precipitation followed 
by HPLC, and Cholesteryl BODIPY FL-C12 (which did not change in response to ethanol) was 
identified using a standard (see Chapter 2). A time course experiment in which larvae were 
treated with ethanol, fed BODIPY FL-C12, and then sampled at intervals 6-22h post-feeding 
revealed that preprandial ethanol exposure is associated with a significant shift toward synthesis 
of phospholipid from dietary fluorescent fatty acids up to 16 hours post-feeding, with an average 
of 1.23-fold more fluorescent phospholipid (quantitated as a percentage of total fluorescence) in 
ethanol-treated larvae with a comparable decrease in triglyceride (n = 3, p<0.05, Student’s T-test) 
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(Figure 4). Ethanol-treated larvae contained an average of 25% more PC(BODIPY FL-C12, 18:1) 
at 6, 9.5, and 16 hours; 39% more PE(BODIPY FL-C12, 16:0) at 6 and 16 hours,  and 22% less 
PC(BODIPY FL-C12, 16:0) at 6 and 22 hours (n = 3, p<0.05, Student’s T-test). Similar 
experiments performed with BODIPY FL-C16 showed no ethanol-associated changes in fatty 
acid partitioning, which is consistent with results obtained from BODIPY FL-C5 and –C12 as 
BODIPY FL-C16 contributes to a minimal amount of phospholipid. In the experiment in Figure 
4, larvae were fed TopFluor-Cholesterol as a feeding control. This BODIPY-lipid is not degraded 
or esterified by larval zebrafish, and may be detected and quantitated by HPLC-Fluorescence in 
the same sample and experiment as the complex lipid products of BODIPY FL-C12. At 6 hours 
post feeding, ethanol-pretreated larvae contain 34% more TF-Chol and 35% more BODIPY FL-
C12 per larva than controls (p = 0.05), while the total BODIPY FL signal does not vary between 
the two groups. At 9.5 hours post-feeding, the ethanol treated group contains 24% more BODIPY 
FL-C12 per larva (p = 0.04) and the total BODIPY FL signal per larva is 20% higher (p = 0.003). 
One possible explanation is that for both of these fluorescent lipids, a saturation point is reached 
and some is excreted without being absorbed. If ethanol slows intestinal peristalsis, then 
unabsorbed substrate in the intestinal lumen would result in a larger HPLC peak for either of 
these analytes. At later time points when the intestine is emptying, unabsorbed substrate would no 
longer be present in larval lipid extracts. It is also possible that ethanol pretreatment results in 
faster uptake of one or both of these fluorescent lipids into enterocytes. While the potential effects 
of preprandial ethanol on feeding, lipid absorption, and excretion require further study, the effect 
of ethanol on channeling of dietary fatty acids into phospholipid is evident no matter which 
quantitation method is used. Planned experiments in which I will investigate potential 




Figure 3. One of four BODIPY FL-C5 phospholipid products increases 1.9-fold with 
preprandial ethanol treatment. Larval zebrafish were treated overnight with 1% ethanol and 
then fed BODIPY FL-C5 in a HF/HC meal. Samples were taken for HPLC-Fluorescence 8 
hours post-feeding, and all complex lipid products of BODIPY FL-C5 were quantitated. The 
amount of PC(22:6, BODIPY-C5) synthesized increased significantly with ethanol treatment 
but the other fluorescent phospholipids and all nonpolar BODIPY FL-C5 products did not 
change. (Nested ANOVA, df = 13) 
$$%!
Figure 4. Preprandial ethanol treatment is associated with increased phospholipid 
synthesis from dietary fluorescent fatty acids. Larval zebrafish were treated overnight with 
ethanol, fed BODIPY FL-C12 in a HF/HC meal, and samples were taken for HPLC-
Fluorescence over a 22-hour time course. * = Time points at which total phospholipids are 
significantly different between control and ethanol-treated groups. ‡ = Time points at which 
total triglycerides are significantly different between control and ethanol-treated groups. 
(Cholesterol BODIPY FL-C12 was measured as well and did not change with ethanol 






LC-MS lipidomics and the zebrafish yolk as lipid metabolism model 
Advances in the precision of LC-MS lipidomics have allowed quantitation of the changes 
in thousands of lipid species in the yolk and body of the developing zebrafish as the yolk is 
absorbed over the first five days of life. This model of lipid transport in a closed system presents 
an opportunity for investigation of roles of specific lipids in development. For example, there is a 
large increase in the molar amount of PC(18:2/20:4) in the yolk over the first 5 days of 
development. Phospholipids carrying 20:4 (arachidonic acid) are the precursor of eicosanoids, 
which are important signaling molecules. Potential roles for eicosanoids in yolk utilization could 
be investigated in this model. A larger question in the MS lipidomics field is the physiological 
significance of changes in rare lipid species; specifically what degree of variability is normal and 
what degree of change would merit follow-up to look for a biological effect.  
Global changes in lipid classes over the course of yolk absorption also suggest avenues of 
future research. For example, the maternally-deposited yolk contains free cholesterol as well as 
cholesterol ester. As cholesterol esterification in cholesterol-absorbing cells such as enterocytes is 
a mechanism for detoxification of excess free cholesterol, the role of cholesterol ester in the yolk 
is unclear. From fertilization to 5 dpf CE moves from the yolk to the body but is not depleted. I 
hypothesize that when the yolk is fully absorbed at 5 dpf, an initial supply of free cholesterol is 
needed until de novo cholesterol synthesis can fulfill demand, and that this need is met by 
breakdown of CE absorbed from the yolk. Potential regulation of the relative amounts of 
triglyceride and cholesterol ester in lipid droplets and lipoproteins is not well-studied. As a larger 
structure rich in netural lipid the embryonic zebrafish yolk would be a good system in which to 
address the relative roles of these two classes of “energy storage” lipids.  
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Characterization of apolipoprotein expression and function in the zebrafish yolk has also 
raised questions that could be investigated further, such as what types of lipoproteins are secreted 
by the yolk and how closely they resemble lipoproteins produced by adult animals. This would be 
important for understanding the range and limitations of the yolk as a model of lipoprotein 
trafficking. Finally, the spatial expression patterns of apolipoprotein genes within the yolk 
suggest a functional regionalization of the yolk that is currently uncharacterized. It is possible that 
variation in apolipoproteins in the yolk is linked to regionalization of the developing intestine	
(195).	
 
Dietary lipid processing in the larval zebrafish intestine 
 Although several families of transporters and lipid-binding proteins have been found to 
play a role in dietary lipid uptake and processing by intestinal enterocytes, their relative 
contributions to lipid absorption, the regulation of their activity, and how they may interact with 
each other have not been determined. For example, results presented in Chapter 2 suggest that 
cholesterol ester synthesis from dietary fatty acids is primarily regulated in response to 
availability of incoming free cholesterol, but the mechanism is unknown. It is also not clear 
whether the cholesterol transport protein NPLC1L1 is directly involved in interactions between 
fatty acid metabolism and cholesterol metabolism. There are multiple membrane-associated fatty 
acid transporters in enterocytes as well, including FATP4, CD36, and Cav1. The relative 
contributions of each of these proteins, non-caveolar endocytosis, and simple diffusion to dietary 
fatty acid uptake are not understood. Furthermore, unlike in the mammalian intestine where it 
localizes to the brush border, Cav1 is expressed only at the basolateral side of the enterocytes of 
larval zebrafish	(62). The functional significance of this difference remains to be determined – 
palmitoleic acid is an important signaling lipid but it is not known whether the change in plasma 
palmitoleic acid concentration observed in Cav1 mutants is physiologically significant. Also, due 
to its subcellular location, I would not expect Cav1 to participate directly in dietary lipid uptake. 
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The mechanism for the effect of Cav1 deletion on plasma and tissue lipid composition is also 
unknown. I hypothesize that changes in albumin trafficking via Cav1 account for changes in lipid 
composition, as albumin is both a caveolar cargo and a fatty acid carrier. 
Additionally, the functional role for specialization of proteins in the ACS and FABP 
(fatty acid-binding protein) families for different subclasses of fatty acids is also not fully 
understood. The ACSs that activate different fatty acids localize to different areas within the cell 
in mammals, but it is unknown whether this applies in zebrafish. As zebrafish express multiple 
paralogs of each ACS it would be interesting to see whether further functional and/or spatial 
specialization occurs.  
Finally, the biology of lipid droplets in enterocytes is an area that lends itself to further 
exploration in the larval zebrafish. Zeituni and colleagues (2016) observed that just after feeding 
a large number of small lipid droplets form in the enterocytes of larval zebrafish and then fuse as 
they mature. Potential consequences of differences in lipid droplet size and number (vs. total 
volume of neutral lipid in the cell) are unknown. One way that ethanol could increase synthesis of 
phospholipid from newly absorbed dietary fatty acids in the intestine is by increasing lipid droplet 
number and decreasing average lipid droplet size. The physiological effects of variation in lipid 
droplet size in the intestine remain to be explored and will be important to consider during 
ongoing work with ethanol. 
 
Remaining questions and technical challenges arising from experiments with ethanol 
Both the live imaging and HPLC-Fluorescence experiments described in Chapter 4 are 
ongoing, and additional method development is required. Initial confocal imaging of larval 
zebrafish livers for the contribution of dietary fatty acids to acute alcoholic steatosis did not allow 
automated quantitation of lipid droplet size, so these experiments should be repeated to obtain 
higher-quality images. Also, these experiments did not show whether all of the fluorescent lipid-
rich structures that accumulated in larval zebrafish undergoing acute alcoholic steatosis were lipid 
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droplets, or if some were other subcellular structures such as endosomes. Transgenic zebrafish 
lines with fluorescently labeled perilipins are now available (Meredith Wilson, unpublished data) 
and will be used to identify lipid droplets in future live imaging experiments. The potential for 
physiological effects from variations in lipid droplet size is a topic of current interest, and 
whether lipid droplet size, number, or both are increased in the larval zebrafish model of acute 
alcoholic steatosis is unknown. Also, the “B-C12” HPLC-Fluorescence instrument method was 
designed primarily with nonpolar lipid resolution in mind, but requires further optimization to aid 
exploration of ethanol’s effect on phospholipid synthesis. Specifically, it is necessary to increase 
separation between the PC(BODIPY FL-C12, 16:0) and PC(BODIPY FL-C12, 18:1) peaks so 
that they can be accurately quantitated. Finally, not all of the fluorescent phospholipid species 
that change with ethanol treatment could be identified by LC-MS/MS, and their phospholipid 
classes (e.g., PC, PS, or PE) should be determined by thin layer chromatography. 
 
Investigating a mechanism for the effect of ethanol on phospholipid synthesis 
 I hypothesize that ethanol drives incorporation of dietary fatty acids into phospholipids 
by damaging membranes in enterocytes, resulting in increased phospholipid synthesis using 
available fatty acids. Of the two major ethanol metabolism pathways, adh1 and cyp2e1, both 
produce aldehydes which can cause cellular damage through protein adduct formation, but the 
cyp2e1 pathway also results in oxidative stress when it is active.  Ethanol may damage enterocyte 
membranes in larval zebrafish by increasing ROS production as it is metabolized. Although 
zebrafish possess both the adh1 and cyp2e1 pathways for ethanol metabolism, adh1 is expressed 
in larvae at <1% of adult levels whereas cyp2e1 expression is equivalent to adult levels by 5 dpf 
(184).  A lack of adh1 activity in larval zebrafish is a possible explanation for the occurrence of 
acute alcoholic steatosis and metabolic changes at levels of ethanol that do not visibly alter 
behavior. This sensitivity of the larval zebrafish liver to ethanol is a strength of the model 
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compared with mice, which require treatment with amounts of ethanol that result in severe 
intoxication to develop acute alcoholic steatosis. Larval dissections followed by HPLC (described 
in Chapter 2, Figures 8 and S5) showed that the partitioning of BODIPY FL-fatty acids into 
complex lipids occurs in the intestine of the larval zebrafish. I hypothesize that ethanol-associated 
changes in dietary lipid metabolism occur in the intestine as well. To test this hypothesis, HPLC-
fluorescence analysis should be performed on intestines dissected from larvae treated with 
ethanol and fed BODIPY-FL fatty acids as described above. Cellular fractionation followed by 
HPLC-fluorescence should also be performed to determine the subcellular location of the 
BODIPY-FL phospholipids that change with ethanol exposure. 
 
Investigating ethanol-associated changes in hepatic lipid composition in adult zebrafish 
Preprandial ethanol induces accumulation of dietary lipid in hepatocytes, in structures 
that appear to be lipid droplets and therefore would consist primarily of neutral lipids. This 
finding seems to contradict the biochemical results which show that dietary fatty acids are being 
channeled toward phospholipid synthesis. However, it is possible that neutral lipids are being 
directed away from other tissues and into storage in the liver, which would not show up in HPLC-
Fluorescence of whole-body lipid extracts. Also, experiments in which intestines, livers, and the 
remainder of the larval body were dissected and separately subjected to HPLC-
CAD/Fluorescence analysis showed that the amount of total lipid in the liver for the sample sizes 
used in these experiments is so low that only cholesterol, which produces a relatively large HPLC 
peak, yields a detectable signal. Because of this, if there are changes in the abundance of 
individual fluorescent or nonfluorescent neutral lipid species in the liver, I would not expect them 
to be detectable against the background of total neutral lipid in whole-larvae extracts.  
 In order to obtain larger volumes of liver tissue for lipid analysis, adult or juvenile 
zebrafish should be fed BODIPY FL-fatty acids mixed into cooked chicken egg yolk following 
ethanol exposure. The lipid content of dissected livers can then be analyzed by HPLC-
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CAD/Fluorescence. Although adults do not exhibit the acute alcoholic steatosis seen in larvae 
(188), the effects of ethanol on dietary lipid partitioning and dietary lipid deposition in 
hepatocytes are not necessarily interdependent. The effect of long-term ethanol exposure on 
dietary lipid metabolism in the intestine and liver of adult zebrafish will also be examined using 
the ethanol treatment procedure designed by Lin and colleagues (188). 
 Potential tissue-specific ethanol-associated changes in neutral lipid composition should 
also be investigated in adult zebrafish. A possible driver of the progression from hepatic steatosis 
to steatohepatitis is lipotoxicity, a process in which lipids stored in non-adipose tissues promote 
cell dysfunction and death (196). As some fatty acids are more likely to promote lipotoxicity than 
others, potential interactions between ethanol and diet that could drive changes in the fatty acid 
composition of the neutral lipid that accumulates in hepatic steatosis could contribute to diet-
dependent variation in the severity of alcoholic liver injury. Lipotoxicity was first demonstrated 
through the observation of impaired beta cell function associated with free fatty acids (196). In 
2001, Schaffer and colleagues published evidence that saturated free fatty acids may promote 
lipotoxicity more than unsaturated free fatty acids, showing that CHO cells underwent apoptosis 
following treatment with the saturated fatty acid palmitate, but not with oleate (a 
monounsaturated fatty acid of similar chain length) (197). Consistent with these cultured cell 
studies, observational studies of humans with cardiac disease and experiments conducted in rats 
have both shown that dietary polyunsaturated fatty acids (PUFAs) protect against lipotoxicity-
induced cell death in the heart when compared with dietary saturated fatty acids(198, 199).  
Lipotoxic effects have been documented in multiple human organ systems and tissues, 
but are not well characterized in the liver (200). The observed effects of dietary saturated fatty 
acids and PUFAs on lipotoxicity in the context of cardiac disease may seem to contradict what is 
known about the reactive properties of ω-3 PUFAs: unsaturated fatty acids can undergo lipid 
peroxidation, which causes inflammation through chain reactions that release reactive oxygen 
species. Fatty liver disease in rodents is improved by diets supplemented with ω-3 PUFAs or 
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tallow (consisting primarily of saturated fats) but worsened by diets supplemented with corn and 
soybean oils (composed primarily of ω-6 PUFAs) (201, 202). Conversely, feeding extremely 
large amounts of ω-3 PUFAs exacerbates fatty liver disease in rodent models. To explain this 
apparent contradiction, I propose a mechanism in which ω-3 PUFAs exacerbate ethanol-induced 
inflammation by undergoing lipid peroxidation when they are released from storage in hepatocyte 
lipid droplets. However, when they are incorporated into hepatocyte membrane phospholipids, I 
hypothesize that ω-3 PUFAs suppress ethanol-induced inflammation by interfering with innate 
immune signaling. Recent evidence from a rodent model suggests that hepatic inflammation 
resulting from ischemia/reperfusion injury depends on localization of the TLR4 receptor in lipid 
rafts, which is inhibited by dietary ω-3 PUFAs (203) . I predict that dietary ω-3 PUFAs that are 
incorporated into membrane phospholipids will suppress inflammation by the same mechanism in 
the context of acute alcoholic liver injury. Under this model, the pro- or anti-inflammatory effect 
of ω-3 PUFAs would be determined by their subcellular localization and incorporation into 
phospholipids or triglycerides.  
 
Potential physiological effects of increased channeling of dietary fatty acids into 
phospholipids 
If it is correct that ethanol channels more dietary fatty acids into membrane phospholipids 
when it is being metabolized concurrently with a meal, then ethanol would amplify the effect of 
diet on membrane composition. This suggests a possible interaction between ethanol and diet that 
could influence cellular signaling, as the fatty acid composition of membrane phospholipids has 
the potential to influence the behavior of membrane-resident proteins (199). This could contribute 
to an explanation of the Mediterranean diet effect, in which a combination of moderate ethanol 
consumption and a diet high in unsaturated fats is associated with lower rates of heart disease	
(204). However, the overall physiological importance of dietary fatty acid partitioning in 
enterocytes for membrane composition in other organs and tissues has yet to be determined. In 
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larval zebrafish, complex lipid profiles of BODIPY FL-C12 products were the same in the 
intestine and the remainder of the body 18 hours post-feeding, but due to the dissipation of 
fluorescent signal after 24 hours it is unknown how long this effect persists. Experiments in adult 
zebrafish, which have more complex lipid regulation pathways due to the presence of adipose 
tissue among other processes, should be performed to address the question of persistence and 
relevance to whole-body membrane lipid composition. Furthermore, all experiments so far have 
been performed using saturated fatty acids as metabolic labels, but the Mediterranean diet 
hypothesis would require ethanol to have similar effects on the channeling of dietary unsaturated 
fatty acids. Metabolic labeling experiments (likely radioactive thin-layer chromatography assays) 
using unsaturated fatty acid substrates would be an important first step toward understanding 
possible mechanisms by which ethanol may interact with diets rich in unsaturated fatty acids to 
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